Ancestral Genomic Functional Differences in Oligodendroglia: Implications for Alzheimer's Disease

Ancestral Genomic Functional Differences in Oligodendroglia: Implications for Alzheimer's Disease | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Ancestral Genomic Functional Differences in Oligodendroglia: Implications for Alzheimer's Disease Aura M Ramirez, Luciana Bertholim-Nasciben, Sofia Moura, Lauren E Coombs, and 23 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-5338140/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background: This study aims to elucidate ancestry-specific changes to the genomic regulatory architecture in induced pluripotent stem cell (iPSC)-derived oligodendroglia, focusing on their implications for Alzheimer's disease (AD). This work addresses the lack of diversity in previous iPSC studies by including ancestries that contribute to African American (European/African) and Hispanic/Latino populations (Amerindian/African/European). Methods: We generated 12 iPSC lines—four African, four Amerindian, and four European— from both AD patients and non-cognitively impaired individuals, with varying APOE genotypes ( APOE3/3 and APOE4/4 ). These lines were differentiated into neural spheroids containing oligodendrocyte lineage cells. Single-nuclei RNA sequencing and ATAC sequencing were employed to analyze transcriptional and chromatin accessibility profiles, respectively. Differential gene expression, chromatin accessibility, and Hi-C analyses were conducted, followed by pathway analysis to interpret the results. Results: We identified ancestry-specific differences in gene expression and chromatin accessibility. Notably, numerous AD GWAS-associated genes were differentially expressed across ancestries. The largest number of differentially expressed genes (DEGs) were found in European vs. Amerindian and African vs. Amerindian iPSC-derived oligodendrocyte progenitor cells (OPCs). Pathway analysis of APOE4/4 carriers vs APOE3/3 carriers exhibited upregulation of a large number of disease and metabolic pathways in APOE4/4 individuals of all ancestries. Of particular interest was that APOE4/4 carriers had significantly upregulated cholesterol biosynthesis genes relative to APOE3/3 individuals across all ancestries, strongest in iOPCs. Comparison of iOPC and iOL transcriptome data with corresponding human frontal cortex data demonstrated a high correlation (R 2 > 0.85). Conclusions: This research emphasizes the importance of including diverse ancestries in AD research to uncover critical gene expression differences between populations and ancestries that may influence disease susceptibility and therapeutic interventions. The upregulation of cholesterol biosynthesis genes in APOE4/4 carriers of all three ancestries supports the concept that APOE4 may produce disease effects early in life, which could have therapeutic implications as we move forward towards specific therapy for APOE4 carriers. These findings and the high correlation between brain and iPSC-derived OPC and OL transcriptomes support the relevance of this approach as a model for disease study. Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 Figure 7 Figure 8 Figure 9 Figure 10 Figure 11 Figure 12 Figure 13 BACKGROUND Alzheimer's disease (AD) is a devastating neurodegenerative disorder characterized by progressive cognitive decline and memory loss. Approximately 11% of people aged ≥ 65 years have AD and this percentage increases with age, reaching 13% of people aged 75–84 years and 33% of people aged 85 years or older. Although age is the strongest risk factor for AD development, genetics plays a critical role in driving AD risk. To date, more than 100 genetic loci have been recognized as predisposing factors for AD through genome-wide association studies (GWAS)[ 1 – 8 ]. Most of these studies have focused on data acquired from non-Hispanic white individuals, with African, African American, and Hispanic/Latino populations being largely underrepresented [ 9 ]. Recently, expanding the representation of these populations in genetic studies has been a growing area of focus, driven in large part by large multicenter collaborations, such as the Alzheimer’s Disease Sequencing Project (ADSP) [ 10 ]. Both Hispanic/Latino and African American populations are admixed populations. Hispanic/Latino individuals’ have differing combinations of European, Amerindian, and African ancestry, while African Americans have primarily African and European ancestry. As such, expanding the representation of other genomic compositions in genomic studies is imperative, as there is clear evidence of differences in risk loci and effect sizes of risk alleles shared across populations. For example, the ε4 allele of the apolipoprotein E ( APOE ) gene represents the most prominent genetic susceptibility factor for late-onset AD, exerting the most pronounced effect on East Asian (EA) populations (Japanese), followed by non-Hispanic White (European) populations, with a comparatively smaller effect in populations of African descent [ 11 – 13 ]. The mechanisms underlying these differences have been shown to be due to ancestry-specific variations in the genomic regulatory architecture (GRA) of the local ancestry surrounding APOE [ 14 – 16 ]. Notably, GRA is not only ancestry biased but also cell type specific. While extensive research has focused on the role of neurons in AD pathogenesis, recent evidence suggests that glial cells, including oligodendrocytes, play crucial roles in the etiology of AD. Oligodendrocytes, which are traditionally known for their role in myelinating axons in the central nervous system [ 17 ], have emerged as key players in AD due to their involvement in various AD-associated pathological processes, including neuroinflammation, oxidative stress, and synaptic dysfunction [ 18 ]. For example, many AD risk genes such as APP, ANK3 , BACE1, BIN1, PICALM, PSEN1, and SORT1 are highly expressed in oligodendrocytes. Additionally, phosphorylated tau in gray matter has been associated with white matter abnormalities and demyelination in AD patients, with these abnormalities appearing prior to the onset of clinical AD symptoms [ 19 ], suggesting the importance of oligodendroglia in AD pathogenesis. For these reasons, we examined and compared the GRA of iPSC-derived oligodendroglia from individuals with significant African (AF), Amerindian (AI), or European (EU) global ancestry. Taken together, our results provide a resource for the AD research community to gain knowledge of genetic factors that may be specific to certain populations, thereby providing a more comprehensive understanding of the disease. METHODS Sample collection. Samples were obtained through genetic studies of AD in African-Americans (R01AG072547 and U01-AG052410), the Puerto Rico Alzheimer Disease Initiative (PRADI) [ 20 , 21 ], and an ongoing study of AD in Peru (R01-AG070864) [ 12 ]. The study was approved by the Institutional Review Boards (IRBs) of the University of Miami and the Universidad Peruana Cayetano Heredia (Lima, Peru). All participants provided informed consent in accordance with the guidelines and regulations of the University of Miami. Cognitive data was obtained on all individuals and was reviewed by a boarded neurologist (J.M.V.), and neuropsychologists (M.C., K.M, A. C-H.) for clinical diagnosis. Induced pluripotent stem cells (iPSCs). Peripheral blood mononuclear cells (PBMCs) were extracted from whole blood using SepMate™-50 tubes with Lymphoprep™ media by density gradient centrifugation according to the manufacturer's protocol (STEMCELL Technologies). PBMCs from AD patients or aged-matched nondemented controls were selected based on their global ancestry (> 90% European, African or Amerindian) (Table 1 ) to be reprogrammed using the CTS™ CytoTune™-iPS 2.1 Sendai Reprogramming Kit (Invitrogen) to generate iPSCs in the Hussman Institute for Human Genomics iPSC Core Facility. Global ancestry estimation The admixture proportion was calculated using a model-based clustering algorithm within ADMIXTURE software [ 22 ]. A supervised ADMIXTURE analysis was conducted at K = 4, incorporating the 4 reference populations (AI, EU, AF, and EA) from combined reference panels of the Human Genome Diversity Project (HGDP) [ 23 , 24 ] and 1000 Genomes Phase 3 [ 25 , 26 ]. Derivation of oligodendrocyte-containing spheroids The iPSC-derived oligodendrocytes underwent differentiation following a previously established protocol [ 27 ] with some minor modifications. Briefly, iPSC lines were cultured on vitronectin-coated plates and maintained in Stemflex™ medium until they reached 70–90% confluency. These cultures were then dissociated into single cells using ACCUTASE™. Once dissociated, the cells were plated on Matrigel®-coated six-well plates at a density ranging from 5^10 5 to 1^10 6 cells per well in StemFlex™ medium supplemented with RevitaCell™. The cells were incubated at 37°C with 5% CO 2 for 1–2 days until colonies with a diameter of approximately 100–250 µm were formed. Upon reaching the desired size, colonies were induced using Neural Induction Media (NIM) supplemented with SB431542 (10 µM), LDN193189 (250 nM), or retinoic acid (100 nM) for 8 days, with daily complete media changes. On day 8, the cells were transitioned to N2 medium (DMEM/F12 with L-glutamine, N2 supplement (1x), non-essential amino acids (NEAA), Penicillin-Streptomycin (PenStrep), and 2-mercaptoethanol) supplemented with retinoic acid (100 nM) and a smoothened agonist (1 µM). The cells were maintained in N2 medium for 4 days, with daily media changes with the addition of fresh supplements. Overconfluent monolayers exhibiting 3D structures were mechanically disrupted in a lattice-like pattern using a scalpel to generate aggregates. The newly formed aggregates were detached from the wells using a cell lifter and plated onto ultralow attachment plates at a 1:2 ratio with N2B27 medium (N2 medium with B27 supplement lacking vitamin A), supplemented with retinoic acid (100 nM) and a smoothened agonist (1 µM). The cells were cultured in N2B27 medium for 8 days, with 2/3 media replacement every other day. The cells were subsequently switched to PDGF medium (DMEM/F12 with L-glutamine, N2 supplement (1x), NEAA, PenStrep, 2-mercaptoethanol, PDGFaa (10 ng/ml), IGF-1 (10 ng/ml), HGF (5 ng/ml), NT3 (10 ng/ml), T3 (60 ng/ml), biotin (100 ng/ml), cAMP (1 µM), and insulin 25 µg/ml) with 2/3 media replacement every other day for 10 days. Round aggregates with a diameter ranging from 300 to 800 µm and a golden or brown appearance were selectively harvested and plated onto PLO/Laminin-coated plates at a density of 20 aggregates per well of a 6 well plate, using Glial medium (DMEM/F12 with L-glutamine, N2 supplement, NEAA, PenStrep, 2-mercaptoethanol, HEPES, T3, biotin, cAMP, insulin, ascorbic acid). The aggregates were maintained in the PLO/Laminin plates for 45 days with 2/3 media replacement every other day. Nuclei isolation for 10x Chromium Single-cell Multiome ATAC + Gene Expression On day 76 after the induction of differentiation, the cultures were harvested, and nuclear isolation was accomplished following a 10x protocol: “Nuclei isolation from complex tissues for single-cell multiome ATAC + gene expression sequencing” with minor adjustments. Briefly, the cultures were detached from the plates using ACCUTASE™ at 37°C for 5 minutes and then washed with PBS + 0.04% BSA. The cell pellet was then resuspended in RDD buffer with DNAse I (0.1 U/µL) and incubated on ice for 5 minutes. After DNAse I treatment, the cells were washed twice with PBS + 0.04% BSA. The pellets were subsequently resuspended in NP40 lysis buffer, incubated on ice for 5 minutes, and homogenized using a pellet pestle with a cordless motor. The homogenate was then filtered through a 40 µm strainer and pelleted. Nuclei resuspension buffer was added to the pellet, followed by a 5-minute incubation on ice. The pellet was then resuspended and washed twice with nuclei resuspension buffer. Lysis efficiency was assessed by staining with trypan blue and nuclei counted using the Countess® II FL Automated Cell Counter. After verification that lysis reached > 95%, the nuclei were pelleted, resuspended in 0.1X lysis buffer, incubated on ice for 2 minutes, washed once with wash buffer, and resuspended in cold diluted nuclear buffer (1x). The number of nuclei was determined using a Cellometer (Nexcelom). The nuclei were diluted to a concentration of 5,500 nuclei/µL for a target cell recovery of 10,000 nuclei. The diluted nuclei suspensions were used for 10x Chromium Single-cell Multiome ATAC + Gene Expression library preparation according to the manufacturer’s protocol. Data analysis RNA-seq The raw RNA-seq data were preprocessed to remove noise, correct for batch effects, and perform quality control checks. Clustering analysis was performed using Seurat's graph-based clustering algorithm to identify distinct cell populations. After clustering, similar nuclei with a final resolution of 0.2 in Seurat were clustered leading to the identification of 11 distinct clusters. Cluster identity was assigned based on the expression of lineage-specific marker genes as follows: 0: Astrocytes; 1: Astrocytes; 2: Excitatory neurons; 3: OPC; 4: Inhibitory neurons; 5: Endothelial; 6: Astrocytes; 7: Cycling progenitors; 8: Oligodendrocytes; 9: Inhibitory neurons; and 10: Excitatory neurons (Supplementary Fig. S1 ). The differential expression of genes (DEGs) between ancestral groups within each cluster was determined using the MAST test, which employs a generalized linear model framework incorporating cell detection rates within replicates and across groups as a covariate [ 28 ]. DEGs were defined as meeting two criteria: p value adjusted < 0.05 and a fold change greater than 1 or less than − 1. Compared with other single-nucleus differential expression methods, the MAST test is known for its low error and false discovery rates [ 29 ]. Pathway analysis The R library gprofiler [ 30 ] was used for functional enrichment analysis. We first selected the gene symbols of down and up regulated genes using adjusted p-value of 0.32 or < -0.32. The function gost was used to perform the gene set enrichment analysis for each comparison using KEGG pathways database. Multiple comparison correction of enrichment scores was done with the ‘gSCS’ method and pathways with p-adj < 0.05 were considered significant. ATAC-seq Analysis of the snATACseq data was performed using the ArchR software package v1.0.1 [ 31 ] as previously described [ 14 ]. Briefly, clustering of cells was performed with five iterations of latent semantic indexing (LSI) followed by batch correction with Harmony [ 32 ]. We created pseudobulk replicates combining all EU, AF, and AI samples separately and called peaks for each ancestry within each cluster via the addReproduciblePeakSet function in ArchR via the default parameters of the MACS2 callpeak command v2.2.7.1 [ 33 ]. Differential accessibility for each peak within each cluster was calculated via ArchR getMarkerFeatures. ATAC peak annotation The function annotatePeak from Chipseeker R library [ 34 ] was used to annotate peaks with the nearest gene and genomic region. The annotation was done at the transcript level using the GENCODE V44 database, with the following priority: "Promoter", "5UTR", "3UTR", "Exon", "Intron", "Downstream", "Intergenic”, and the distance of ± 3 kb from the transcription start sites (TSS) was used to assign a peak to a gene promoter-TSS. Hi-C The in situ Hi-C libraries were constructed following the protocol outlined by Rao et al. [ 35 ]. In summary, each library yielded 450–550 million paired-end 150 base pairs reads. Over 270 million nonredundant, uniquely mapped, paired end reads were subsequently utilized for further analysis of each library. Contact matrices were created at resolutions of 500 kb, 50 kb, and 5 kb. The Directionality Index (DI) value of 40 kb bins was employed to identify the topologically associated domains (TADs). To accurately map enhancer‒promoter interactions, the HiCorr pipeline was employed to correct for Hi-C bias at the sub-TAD level and identify Hi-C loops [ 35 ]. RESULTS Generation of ancestry-specific iPSCs and iPSC-derived oligodendroglia We generated a total of 12 iPSC lines (four African, four Amerindian, and four European) in this study, of which six were from AD patients and six were from non-cognitively impaired individuals (Table 1 ). In addition, we had four APOE4/4 carriers and eight APOE3/3 carriers. We differentiated these 12 lines into neural spheroids producing oligodendrocyte lineage cells at different maturation stages ranging from cycling progenitors through to mature myelinating oligodendrocytes. In addition to oligodendrocyte-related cells, the spheroids contained neurons and astrocytes based on immunocytochemistry (Fig. 1 A) and snRNA-seq (Fig. 1 B- 1 C) analyses. Table 1 List iPSC lines used in this study. HIHG ID​ Source 1 Sex 2 APOE genotype Global Ancestry Diagnosis 3 ​ Age Global Ancestry 4 AI EU AF EA 201816444​ This study F 4/4​ AF AD 67 0.006 0.050 0.944 0.000 201505672 This study F 3/3 AF NCI 72 0.000 0.036 0.964 0.000 202001540​ This study F 3/3 AF AD 84 0.003 0.082 0.915 0​.000 201917729​ This study F 3/3 AF MCI 90 0.019 0.046 0.935 0.000 202001087​ This study F 4/4​ AI AD​ 86 1.000 0.000 0.000 0.000 202001079​ This study F 3/3​ AI NCI 71 0.920 0.077 0.000 0.002 201917151 This study M 3/3​ AI NCI 86 0.955 0.042 0.000 0.003 202001121 This study M 3/3​ AI NCI 86 0.963 0.011 0.013 0.013 201806025 ADRC F 4/4 EU AD 75 0.002 0.995 0.004 0.000 201806023 ADRC F 3/3 EU NCI 70 0.007 0.938 0.055 0.000 201806022 ADRC F 3/3 EU NCI 65 0.000 0.997 0.003 0.000 201616981 This study F 4/4 EU AD 76 0.050 0.886 0.048 0.016 1 ADRC= Alzheimer's Disease Research Center (UCI) 2 F=Female ; M = Male 3 AD=Alzheimer’s disease ; NCI = Non-Cognitively Impaired ; MCI = Mild cognitive impairment 4 Global ancestry was calculated using admixture software. Refer to Methods for more details. Single-nuclei transcriptional profiling of iPSC-derived oligodendroglia containing neural spheroids across diverse ancestries. Attempts to isolate individual cell types from the tightly clustered spheroids via FACS or pull-down procedures resulted in a low yield of viable cells. To overcome these difficulties in recovery and minimize the manipulation of the cells, single-nuclei approaches were used to analyze the transcriptional states of the cells in these oligodendrocyte-enriched neural spheroids. These analyses were performed across the 12 iPSC lines from the three ancestral populations. We characterized a total of 47,898 cells, with an average of 3,991 ± 1,608 per sample. Seurat-based pattern recognition clustering identified seven cell clusters shared by all the individual samples (Fig. 1 B and Supplementary Fig. S2 ). We subsequently detected genes that were enriched in each cluster and utilized these for the assignment of cell types to each individual cluster. We identified one OPC cluster (enriched for the expression of PDGFRA , COL20A1, OLIG1, OLIG2, and PTPRZ1 ) (Fig. 1 B- 1 C) and one oligodendrocyte (OL) cluster ( MOG, CLDN11, ENPP6, MYRF, and MBP) (Fig. 1 A- 1 B) among other cell types, including astrocytes, excitatory and inhibitory neurons, endothelial cells, and cycling progenitors. Differentially expressed genes (DEG) between ancestries To investigate ancestry-related changes in the transcriptome of the oligodendroglia found in our cultures, we performed differential gene expression analyses using pairwise comparisons of the OPC and oligodendrocyte clusters independently (shown in Fig. 2 and Table 2 ). In the OPC cluster, we found that the number of DEGs was greatest in the European vs. Amerindian comparisons, with a total of 1,750 DEGs (Fig. 2 A, Tables 2 and S1) and approximately 90% (1,573) were increased in the European samples. On the other hand, in the OL cluster, the greatest number of DEGs was found between the African and Amerindian lines, with 492 DEGs, of which ~ 87% (427), were increased in the African lines (Fig. 2 D, Tables 2 and S4). To identify DEGs common to the oligodendroglia lineage, we analyzed the data to identify overlapping DEGs in both clusters for each comparison (shown in Table 2 ). Table 2 Differentially expressed genes (DEGs) across ancestries. Total number of DEGs found in each pairwise comparison between different ancestries. TOTAL GENES (AD GWAS) iOPC iOL iOPC ∩ iOL EU > AI 1573(8) 1750 290(3) 345 208(0) 246 AI > EU 177(1) 55(0) 38(0) AF > AI 1007(6) 1209 427(2) 492 250(0) 297 AI > AF 202(3) 65(0) 47(0) AF > EU 181(0) 264 49(1) 74 35(0) 45` EU > AF 83(2) 25(1) 10(0) ∩: Denotes shared DEGs between the iOPC and iOL clusters Ancestry-dependent changes in AD We compared the DEGs obtained from the different comparisons to genes currently implicated as AD GWAS loci [ 1 , 3 , 8 , 36 , 37 ]. We found eleven AD GWAS genes ( ALCAM, APP, COX7C, EGFR, GPC6, MYO15A, PLCG2, RTN1, SEC61G, SORL1, and TMEM106B ) to be differentially expressed between the ancestries in the iOPC cluster (Fig. 3 A, Table 3 ). On the other hand, in the iOL cluster, only five AD GWAS hits were differentially expressed: ADAM17, CLU, EPDR1, FGF12, MAF and WWOX (Fig. 3 B, Table 3 ). One additional interesting DEG was OPCML , a gene that has recently been linked to AD [ 38 – 40 ]; in this case, we found it to be increased in Europeans compared with Africans. Table 3 Differentially expressed AD GWAS genes across ancestries Comparison Gene Fold Change p_val_adj DEG between males and females* AF vs AI OPC GPC6 1.27 8.24E-09 Yes ALCAM 1.26 1.42E-10 Yes APP 1.26 1.83E-04 No COX7C -1.30 1.66E-02 No SEC61G -1.38 1.49E-02 No RTN1 -1.48 6.21E-04 No EGFR -1.82 1.83E-06 No SORL1 -1.96 2.57E-17 Yes MYO15A -3.26 7.87E-03 No EU vs AI OPC FGF12 1.52 2.77E-06 No CTSB -1.39 4.80E-03 Yes COX7C -1.43 8.05E-17 No PLCG2 -1.46 5.08E-11 Yes TMEM106B -1.47 1.63E-08 No ENC1 -1.48 1.45E-02 Yes SORL1 -1.64 1.94E-08 Yes SEC61G -1.76 5.28E-15 No EGFR -1.88 3.57E-18 No EU vs AF OPC GPC6 -1.31 9.75E-05 Not applicable PLCG2 -1.61 7.95E-10 Not applicable AF vs AI OL WWOX -1.34 1.95E-05 No MAF -2.20 1.47E-02 No EU vs AI OL WWOX -1.33 9.59E-03 No ADAM17 -1.56 2.40E-03 No EPDR1 -2.01 4.98E-02 No EU vs AF OL FGF12 1.27 3.16E-02 Not applicable CLU -1.63 3.75E-02 Not applicable *Found to be differentially expressed between AI male and AI female samples in this study (Tables S4 and S8) Transcriptome comparisons between APOE 3/3 vs APOE 4/4 To investigate the transcriptional changes that occur in oligodendroglia dependent on the APOE genotype, we compared the APOE3/3 lines with the APOE4/4 lines irrespective of their ancestry. For the larger iOPC cluster, there were 5,578 DEGs (Fig. 4 A, Table S17), 30 of which are known AD GWAS loci; interestingly, most of them were upregulated in the 4/4 lines compared with the 3/3 lines (Fig. 4 A, 4 B), with the exceptions of IGF1R, IDUA, SORT1, ALCAM, MGMT, FGF12 and ARAP1. In the iOL cluster, we identified 1,653 DEGs, including 9 AD GWAS genes namely, RTN1, VSNL1, SORL1, COX7C, ANK3, ALCAM, ADAM10, IGF1R and MGMT (Fig. 4 C, 4 D, Table S18). A total of 1,075 DEGs were shared by both clusters, including the AD GWAS genes ALCAM, ANK3, COX7C, IGF1R, MGMT, RTN1, SORL1 and VSNL1 (Tables S17 and 18). To determine whether the overlapping DEGs in oligodendroglia when analyzed by APOE genotype and AD status were involved in specific processes, we performed pathway analysis on these DEGs (Fig. 5 ). These analyses showed that a wide range of pathways, especially those associated with neurodegenerative diseases, are significantly upregulated in APOE4/4 carrier iOPCs compared to APOE3/3 carriers. Many of these pathways are involved in neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease (Fig. 5 A). Interestingly, fewer disease-related and more general pathways were identified in iOLs (Fig. 5 B). The largest number of genes in iOPCs were involved in metabolic pathways, which led us to test for those involved in cholesterol biosynthesis. Indeed, a large number of DEGS were specifically increased in the cholesterol biosynthesis pathway in APOE4/4s compared to APOE3/3 iOPCs (Fig. 6 ). Further, we observed reduced expression of MBP, PDGFRA , and MYRF , key genes in myelin formation in the APOE4/4 iOPC lines. Finally, Fig. 5 C and 5 D shows pathway differences observed between NCI and AD iOPCs and iOLs. These pathways were similar to those seen in the APOE 3/3 vs APOE 4/4 comparison likely due to the fact that the majority of AD samples had the APOE4/4 genotype. iOPC and iOLs correlated well with brain transcriptomes To further validate the identity of our oligodendroglia, we ran Spearman correlation tests to compare our iOPC and OLs iOLs with gene expression patterns from the same cell types in human brain samples [ 15 ]. The correlation coefficient between iOPCs and brain OPCs was 0.89 and that between iOLs and brain OLs was 0.85, suggesting that our iOligodendroglia are transcriptionally similar to brain oligodendroglia from aged individuals. Males vs Females Expression To account for sex-driven differences, given that most of our samples were females, except for two of the Amerindian lines, we performed differential expression analyses between the two AI males and the two AI females. It is worth noting that we observed loss of X chromosome inactivation (chromosome X erosion) in the female AI samples (Tables S4 and S8) [ 41 ], suggesting that the expression of genes on the X chromosomes and those influenced by them could be affected. Y chromosome genes were expressed as expected (e.g. UTY and USP9Y were expressed in the male derived spheroids but not the female derived). We found that ALCAM , GPC6 and SORL1 were differentially expressed between males and females in the iOPC cluster (Tables 3 and S4). On the other hand, none of the AD GWAS genes that were differentially expressed between ancestries were differentially expressed between males and females in the iOL cluster (Tables 3 and S8). Pathway analysis between ancestries Pathway analysis between ancestries is shown in Fig. 7 . Oxygen species production, diabetic cardiomyopathy, steroid biosynthesis, and several neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Alzheimer's disease, were identified in the pathway analyses. Interestingly, pathways of neurodegeneration implicated in multiple diseases, including Alzheimer's disease, were shown to be enriched for DEGs in Amerindian iOPC and iOL compared with those from European and African ancestries (Fig. 7 C and Fig. 7 D). The DEGs whose expression was increased in European oligodendroglia compared with Amerindian oligodendroglia did not appear to converge into any defined pathways. Finally, in the European vs. African comparison, the DEGs enriched in the European samples were also involved in several neurodegenerative disease pathways, specifically Huntington's disease and ALS, in addition to neuronal signaling processes (Fig. 7 E). Single-nucleus chromatin accessibility profiling of iPSC-derived oligodendroglia-enriched neural spheroids across diverse ancestries. To characterize chromatin accessibility profiles associated with different ancestries, we performed single-nuclei ATAC sequencing of oligodendroglia enriched in neural spheroids derived from the 12 iPSC lines. We characterized a total of 76,409 nuclei, with an average of 6,367 ± 3,994 per line. ArchR-based pattern recognition clustering identified 8 cell type clusters shared by all the individual samples (Fig. 8 A). Based on marker genes, we identified one OPC (C6) cluster and one oligodendrocyte cluster (C7) (Fig. 8 B). To investigate the ancestry-related changes in chromatin accessibility in the oligodendroglia clusters, we performed pairwise comparisons of the iOPC and iOL clusters independently (shown in Fig. 9 ). For the AF vs. AI comparison in the iOPC cluster, we found 412 differentially peaks (DAPs) distributed across 357 genes, including RBFOX1, PRDM7 , NCK2, EPDR1, and IQCK (AD GWAS hits) (Fig. 9 A, Table S9). The number of DAPs between EU and AI was 413, belonging to 351 different genes, including the AD GWAS genes ADAM17, BIN1, CTSB, ECHDC3, EGFR, IGF1R, MAPT, MGMT , and RBFOX1 (Fig. 9 B, Table S10). We also found DAPs associated with FGF12 and PRDM7 , but these same peaks were also found when we compared the two female AI lines to the two male AI lines, limiting our ability to distinguish ancestry-related or sex-related differences in these genes. When comparing the EU to the AF, we found a total of 457 DAPs (Fig. 9 C, Table S11). These peaks were distributed across 373 genes, including four AD GWAS hits: RBFOX1, PRDM7, FGF12, JAZF1, PRDM7, PRDM7 , and IQCK. On the other hand, for the iOL cluster, the greatest number of DAPs was found between AI and EU, with a total of 162 DAPs across 139 genes, including PDRM7 , ADAMTS1 , and REXO1 (Fig. 9 E). However, these DAPs were also found in the male vs. female comparison suggesting that the differences seen in accessibility of these genes could be due to sex differences rather than ancestry. We identified 73 DAPs across 63 genes, including a peak in PDRM7 that was also present in the male vs. female analysis in the comparison between AFs and AIs (Fig. 10 E). Finally, we found 49 DAPs across 39 genes between Africans and Europeans, including the AD GWAS risk gene FGF12 (Fig. 10 F). Genomic Regulatory Architecture To examine the relationship between DEG and DAPs, we compared the genes associated with the DAPs with those that showed differential expression for each pairwise comparison in both oligodendroglia clusters – iOPCs and iOLs (Fig. 10 ). In the iOPC cluster, we identified 60 genes that were differentially accessible and differentially expressed between Amerindians and Africans (Fig. 10 A, Table S9). To account for sex-driven differences, we performed differential accessibility analyses comparing the 2 AI males to the 2 AI females (Table S12). Only 17 of the 60 were not found to be differentially expressed/accessible in the comparisons between males and females (Tables S4, S8, S12 and S16); for all of them, increased accessibility was correlated with increased expression. For the AI vs. EU comparison, we found 49 genes that were differentially accessible and differentially expressed; of these, 3 were previously reported AD GWAS genes ( CTSB, EGFR and FGF12 ) [ 1 , 4 , 42 ] (Fig. 10 B, Table S10). Among these 49 genes, 23 were not affected by sex and 87% of this accessibility was correlated with expression. The exceptions were MAP2, PPP2R2A and PDXDC1 ; however, the last gene had two peaks, one in the promoter that correlated with expression and one in an exon that showed an inverse correlation (Table S2 and S10). Finally, in the AF vs. EU comparison, we found 22 DAGs that overlapped with the DEGs we identified (Fig. 10 C); in all cases, accessibility correlated with expression, but for one of the genes harboring 2 DAPs, only one located in the promoter region correlated, whereas the other, located at an intron, showed the opposite trend (Table S3 and S11). In the iOL cluster, we found 10 overlapping DAGs and DEGs in the AI versus AF comparison (Fig. 10 D, Table S5 and S13), 3 of which were not affected by sex and had direct correlation between accessibility and expression, and 10 in the AI versus EU comparison (Fig. 10 E, Table S6 and S14); of these, 7 were not found to be influenced by sex (Table S16), and the accessibility of the peaks was in accordance with their expression. Ancestry-specific differences in FGF12 chromatin openness and expression When we looked at the DAP linked to FGF12 (Fig. 11 , yellow highlight, Table S15), we observed that accessibility was correlated with FGF12 expression (Fig. 3 B), as shown by the absence of a open chromatin peak in the EU lines and corresponding reduction in FGF12 expression in EU compared with the other two ancestries. Interestingly, within this peak, there is a site registered on ENCODE as a candidate cis-regulatory element with a proximal enhancer-like signature – histone modification H3K4me3 (ENCODE Accession: EH38E2269814) (Fig. 11 ). Additionally, ORegAnno analysis showed this region also contains a transcription factor binding site for CTCF (ORegAnno ID: OREG1365260) (Fig. 11 ). Further, Hi-C analyses showed chromatin loops occurring between this ATAC peak and the transcriptional start site of the non-coding RNA ENSG00000289165, an antisense to FGF12 , in spheroids and brain samples (Fig. 11 ). This finding suggests that transcription of FGF12 could be modulated in an ancestry-dependent manner by this non-coding RNA. APOE genotype-based comparisons When comparing APOE3/3 iOPCs to their APOE4/4 counterparts, we identified a total of 67 DEGs that had corresponding DAPs. Of these, 3 were AD GWAS genes – EGFR, EPDR1 , and FGF12 (Fig. 12 A-B, Tables S17 and S21). Additionally, we identified a DAP associated to ADAM17 (Fig. 12 A-B)., a gene previously reported as an AD GWAS gene thought to be involved in TREM2 processing and regulating APP expression and therefore Aß formation [ 43 ]. On the other hand, in the iOL cluster, only 16 DEGs with corresponding DAPs were identified. None of these iOligodendroglia-specific DAPs have, as of yet, been linked to AD (Fig. 12 C-D, Tables S17 and S21). Disease status-based comparisons When comparing the NCI lines to AD iOligidendroglia, we identified 38 DEGs that had corresponding DAPs, including 2 AD GWAS genes – FGF12 and MGMT (Fig. 13 A-B, Tables S19 and S23). Additionally, we identified DAPs associated with EPDR1 and JAZF1 , but these genes were not differentially expressed in this comparison (Fig. 13 A-B). Finally, in the OL cluster, we found only 2 DEGs with DAPs, none of which were AD GWAS genes (Fig. 13 C-D Tables S20 and S24). Discussion In this study, we compared the chromatin accessibility and transcriptomes of the three different ancestries that contribute to the African American and Hispanic/Latino admixed populations. Most previous studies have focused on the analysis of Europeans. Thus, this study provides new information and iPSC resources on these previously underrepresented ancestries. While we are focused on AD, the data generated can be more broadly applied to other disorder involving OPCs and OLs. Overall, our studies show that chromatin accessibility and transcriptomes are similar for the three ancestries, although several key known AD genes showed ancestry-specific patterns of expression and/or chromatin openness that may reflect differences in risk between the ancestries. This ancestral similarity was particularly true for the chromatin structure analyses (ATACseq). Our data supports that DEG and DAP for the corresponding genes at AD GWAS loci are not a major factor in most comparisons. This is not to say that the AD (or other disease) GWAS loci that have common or different patterns of expression and chromatin openness will have similar causal mechanisms. We may well find that chromatin conformation analysis (i.e. Hi-C studies) will identify unique differences. Further, while single nuclei approaches have significant power to identify differences between individuals, the overall representation of a population is limited by the number of individuals that can be included in iPSC studies. However, the similarity between ancestries in both accessibility and expression in iOPC and iOLs across the majority of genes is reassuring for future therapeutic efforts in AD. Both APOE4/4 and APOE3/3 carriers across all the ancestries were included in this study. We found that APOE4/4 carriers across all ancestries and in multiple individuals had clear upregulated expression of genes involved in cholesterol biosynthesis, particularly in iOPCs. The lower numbers of differential genes in iOLs could be due to the relatively fewer numbers of these cells found in this cluster within these cultures. This finding builds upon a similar observation seen in APOE4/4 oligodendrocytes and OPCs from brain prefrontal cortex in previous studies [ 44 ]. Blanchard et al found similar results in a single isogenic APOE 3/3 APOE4/4 iOL line [ 44 ]. Thus, cholesterol dysregulation appears to occur early in life during early stages in the development of oligodendrocytes (OPC) leading to impaired cholesterol and lipid biosynthesis. Even mild differences in cholesterol and lipid metabolism by oligodendroglia, occurring over the course of a lifetime, could produce pathogenic results. Indeed, research has highlighted the importance of white matter abnormalities in AD, including those involving oligodendroglia and myelin [ 18 , 19 , 45 – 47 ]. White matter abnormalities are considered early neuropathological events in AD since white matter hyperintensities, suggesting damage, have been observed preceding the development of AD symptoms [ 19 ]. These irregularities in white matter may play a significant role in the pathogenesis of AD and be of considerable diagnostic value [ 19 ]. Clinically, there have been reports of early AD-associated anatomical changes in infants and children. For example, Dean et al., reported that in areas affected by AD infants carrying APOE4 had lower white matter myelin water fractions on magnetic resonance imaging (MRI) compared to non-carriers [ 48 ]. Further, Remer et al., found in young APOE4 carriers a slower rate of myelination in multiple brain regions compared to that of non-carriers [ 49 ]. Thus, our findings in iOPCs and OPCs have potential implications for future timing of therapy for APOE4 carriers [ 50 ]. We showed that our 3D neural spheroids produce brain-like oligodendroglia with transcriptomes that had high correlation > 85% with human brain oligodendroglia datasets, including OPCs and a population of early myelinating oligodendrocytes characterized by high expression of BCAS1 (Fard et al., 2017). Additionally, we observed that our ancestry-based data replicates findings from human brain studies. For example, we found CLU to be differentially expressed between AF and EU iOLs as previously reported by Griswold et al. in AD human brains [ 15 ]. These observations suggest that iOPC and iOLs are a good model to study oligodendroglia that effectively reflects phenomena occurring in vivo in human brains. OPCs, which are central nervous system (CNS) resident stem cells that are spread throughout the brain forming a category of mobile and actively dividing adult precursor cells capable of developing into oligodendrocytes [ 51 ]. OPCs play a very important role in the response to myelin damage due to injury or disease, as they are responsible for maintaining the population of oligodendrocytes and participate in myelin repair [ 52 , 53 ]. In AD, the brain's microenvironment undergoes detrimental changes that significantly impact OPCs and their functionality [ 54 ]. The observed changes in OPCs suggest reduced differentiation capacity and elevated OPC senescence [ 55 ]. These changes can have implications for myelin maintenance and repair, as well as for the overall integrity of the central nervous system [ 54 , 55 ], thereby making OPCs a highly relevant cell population for the study of AD. In this context, this report is the first study focusing on human iPSC-derived oligodendroglia that includes samples from different ancestries. When we isolated the pathway changes in cholesterol biosynthesis to specific ancestries, we found that several of the cholesterol biosynthesis genes are increased in AI compared to AF and EU Oligodendroglia (Tables S4 and S8). This finding is interesting in light of epidemiological observations in AI populations which suggest that evolutionary pressures favored the increased expression of lipid metabolism genes (including APOE4 ) to overcome food scarcity and endemic infectious diseases (high cholesterol supports innate immunity) in AI groups, particularly in Indigenous groups in South America [ 56 ]. This is also believed to be a reason APOE4 has its highest global frequency in specific regions of South America and Africa [ 57 ]. Finally, the inclusion of multiple ancestries in AD research not only supports the importance of reducing health disparities in AD, the comparison of differences between ancestries is a useful research tool in exploring the mechanisms of disease. While the outcome of AD may be similar across ancestral populations, the starting points and biological paths taken in the development of AD may differ between genetic ancestries and environments. Thus, studies on diverse populations provide novel windows into the pathology of AD which will only help move us towards the ultimate goal of prevention. CONCLUSIONS This study represents a significant advancement in understanding the ancestry-specific differences in iPSC-derived oligodendroglia and their implications for Alzheimer's disease (AD). By generating and analyzing iPSC lines from AF, AI, and EU ancestries, we have identified unique transcriptional and chromatin accessibility profiles in genes that may contribute to AD risk. Our findings emphasize the importance of including diverse ancestries in iPSC studies to uncover subtle yet crucial differences that may impact disease susceptibility and progression. The differential expression and accessibility of genes associated with AD across ancestries, such as APOE, highlight potential pathways that could be targeted for therapeutic interventions. Notably, the upregulation of cholesterol biosynthesis genes in AI iPSC-derived oligodendroglia suggests evolutionary adaptations that may confer advantages in certain environments. Although these alterations may promote survival in the face of potential food scarcities, they may have come at the cost of increasing risk for AD development. This study also underscores the role of APOE genotype in modulating gene expression related to lipid metabolism, providing insights into early intervention strategies for APOE4 carriers. The correlation between our iPSC-derived models and human brain oligodendroglia strengthens the validity of using these models to study neurodegenerative diseases, offering a promising avenue for future research in AD biology and therapeutic development. Finally, this work not only sheds light on the molecular underpinnings of AD across different genetic backgrounds but also underscores the necessity to address health disparities by ensuring diverse representation in research. Understanding the distinct genetic and environmental pathways leading to AD in various populations will enhance our ability to develop effective, personalized prevention and treatment strategies. Abbreviations AD Alzheimer’s disease MCI Mild cognitive impairment NCI Non cognitively impaired GWAS Genome wide association studies GRA Genomic regulatory architecture AF African AI Amerindian EU European EA East Asian WGS Whole Genome Sequencing iPSC induced pluripotent stem cells OPC Oligodendrocyte precursor cells OL Oligodendrocytes iOPC iPSC derived OPC iOL iPSC derived OL DEG Differentially expressed gene DAP Differentially accessible peak DAG Differentially accessible gene GA Global ancestry Declarations Ethics approval and consent to participate: The research protocols involving the collection of human samples were reviewed and approved by the Institutional Review Board (IRB) at the University of Miami. The IRB approval ID for this study is CR00001611. All procedures were conducted in accordance with ethical standards and guidelines for research involving human participants. Consent for publication Not applicable. Availability of data and materials All data generated and analyzed for this study are included in this published article and its supplementary information files. Additional raw files are available from the corresponding author upon reasonable request. Competing interests The authors declare that they have no competing interests. Funding This research was funded by the National Institute on Aging through the following grant numbers: U01-AG072579, RF1-AG059018, U01-AG066767, U01-AG052410, R56-AG072547, and R01-AG070864. Additional funding was received from a Zenith Award (Alzheimer’s Association, J.M.V) and the BrightFocus foundation. Authors' contributions A.M.R., D.M.D., A.J.G., J.I.Y., and J.M.V. conceptualized the project and designed the experiments. A.M.R. conducted the experiments. A.M.R., L.B.N., and A.J.G. analyzed the data. S.M, and L.C. contributed to the execution of the experiments and performed the iPSC reprogramming, while B.A.D. assisted with this process. J.R. and F.R. carried out local and global ancestry analyses. P.W., L.D.A., T.D.S., P.M., M.I.-M., S.T., G.B., M.C.-O., B.F.-A., and M.A.P.-V. were involved in sample collection and processing. L.W. and M.R. processed the samples for Hi-C analyses, W. X., F.J performed the bioinformatic analysis for the Hi-C data. A.M.R., L.B.N., S.M., F.R., A.J.G., D.M.D., J.I.Y., and J.M.V. discussed the data results. A.M.R., L.B.N., A.J.G., D.M.D., J.I.Y., and J.M.V. wrote the manuscript. All authors reviewed and approved the final manuscript. Acknowledgements We would like to thank the Center for Genome Technology (CGT) at the John P. Hussman Institute for Human Genomics (HIHG) at the University of Miami, Miller School of Medicine, for their support in processing the samples for library preparation and sequencing. We are also grateful to the many participants, researchers, and staff who contributed significantly to this study. References Bellenguez, C., et al., New insights into the genetic etiology of Alzheimer's disease and related dementias. Nat Genet, 2022. 54 (4): p. 412-436. Kunkle, B.W., et al., Genome-wide linkage analyses of non-Hispanic white families identify novel loci for familial late-onset Alzheimer's disease. Alzheimers Dement, 2016. 12 (1): p. 2-10. Kunkle, B.W., et al., Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel: A Meta-analysis. JAMA Neurol, 2021. 78 (1): p. 102-113. Lake, J., et al., Multi-ancestry meta-analysis and fine-mapping in Alzheimer's disease. Mol Psychiatry, 2023. 28 (7): p. 3121-3132. de Rojas, I., et al., Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. Nat Commun, 2021. 12 (1): p. 3417. Naj, A.C., G.D. Schellenberg, and C. Alzheimer's Disease Genetics, Genomic variants, genes, and pathways of Alzheimer's disease: An overview. Am J Med Genet B Neuropsychiatr Genet, 2017. 174 (1): p. 5-26. Xue, D., et al., Large-scale sequencing studies expand the known genetic architecture of Alzheimer's disease. Alzheimers Dement (Amst), 2021. 13 (1): p. e12255. Lill, C.M. and L. Bertram, Genome-wide analysis furthers decoding of Alzheimer disease genetics. Nat Rev Neurol, 2022. 18 (7): p. 387-388. Lambert, J.C., et al., Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet, 2013. 45 (12): p. 1452-8. Beecham, G.W., et al., The Alzheimer's Disease Sequencing Project: Study design and sample selection. Neurol Genet, 2017. 3 (5): p. e194. Rajabli, F., et al., A locus at 19q13.31 significantly reduces the ApoE epsilon4 risk for Alzheimer's Disease in African Ancestry. PLoS Genet, 2022. 18 (7): p. e1009977. Marca-Ysabel, M.V., et al., Dissecting the role of Amerindian genetic ancestry and the ApoE epsilon4 allele on Alzheimer disease in an admixed Peruvian population. Neurobiol Aging, 2021. 101 : p. 298 e11-298 e15. Farrer, L.A., et al., Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA, 1997. 278 (16): p. 1349-56. Celis, K., et al., Ancestry-related differences in chromatin accessibility and gene expression of APOE epsilon4 are associated with Alzheimer's disease risk. Alzheimers Dement, 2023. 19 (9): p. 3902-3915. Griswold, A.J., et al., Increased APOE epsilon4 expression is associated with the difference in Alzheimer's disease risk from diverse ancestral backgrounds. Alzheimers Dement, 2021. 17 (7): p. 1179-1188. Rajabli, F., et al., Ancestral origin of ApoE epsilon4 Alzheimer disease risk in Puerto Rican and African American populations. PLoS Genet, 2018. 14 (12): p. e1007791. Baumann, N. and D. Pham-Dinh, Biology of oligodendrocyte and myelin in the mammalian central nervous system. Physiol Rev, 2001. 81 (2): p. 871-927. Cai, Z. and M. Xiao, Oligodendrocytes and Alzheimer's disease. Int J Neurosci, 2016. 126 (2): p. 97-104. Nasrabady, S.E., et al., White matter changes in Alzheimer's disease: a focus on myelin and oligodendrocytes. Acta Neuropathol Commun, 2018. 6 (1): p. 22. Feliciano-Astacio, B.E., et al., The Puerto Rico Alzheimer Disease Initiative (PRADI): A Multisource Ascertainment Approach. Front Genet, 2019. 10 : p. 538. Akgun, B., et al., Genome-wide association analysis and admixture mapping in a Puerto Rican cohort supports an Alzheimer disease risk locus on chromosome 12. Front Aging Neurosci, 2024. 16 : p. 1459796. Alexander, D.H., J. Novembre, and K. Lange, Fast model-based estimation of ancestry in unrelated individuals. Genome Res, 2009. 19 (9): p. 1655-64. Clarke, L., et al., The international Genome sample resource (IGSR): A worldwide collection of genome variation incorporating the 1000 Genomes Project data. Nucleic Acids Res, 2017. 45 (D1): p. D854-D859. Fairley, S., et al., The International Genome Sample Resource (IGSR) collection of open human genomic variation resources. Nucleic Acids Res, 2020. 48 (D1): p. D941-D947. Delaneau, O., et al., Integrating sequence and array data to create an improved 1000 Genomes Project haplotype reference panel. Nat Commun, 2014. 5 : p. 3934. Genomes Project, C., et al., A global reference for human genetic variation. Nature, 2015. 526 (7571): p. 68-74. Douvaras, P. and V. Fossati, Generation and isolation of oligodendrocyte progenitor cells from human pluripotent stem cells. Nat Protoc, 2015. 10 (8): p. 1143-54. Finak, G., et al., MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data. Genome Biol, 2015. 16 : p. 278. Soneson, C. and M.D. Robinson, Bias, robustness and scalability in single-cell differential expression analysis. Nat Methods, 2018. 15 (4): p. 255-261. Kolberg, L., et al., gprofiler2 -- an R package for gene list functional enrichment analysis and namespace conversion toolset g:Profiler. F1000Res, 2020. 9 . Granja, J.M., et al., ArchR is a scalable software package for integrative single-cell chromatin accessibility analysis. Nat Genet, 2021. 53 (3): p. 403-411. Korsunsky, I., et al., Fast, sensitive and accurate integration of single-cell data with Harmony. Nat Methods, 2019. 16 (12): p. 1289-1296. Zhang, Y., et al., Model-based analysis of ChIP-Seq (MACS). Genome Biol, 2008. 9 (9): p. R137. Yu, G., L.G. Wang, and Q.Y. He, ChIPseeker: an R/Bioconductor package for ChIP peak annotation, comparison and visualization. Bioinformatics, 2015. 31 (14): p. 2382-3. Rao, S.S., et al., A 3D map of the human genome at kilobase resolution reveals principles of chromatin looping. Cell, 2014. 159 (7): p. 1665-80. Kunkle, B.W., et al., Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. Nat Genet, 2019. 51 (3): p. 414-430. Zhang, L., et al., Epigenome-wide meta-analysis of DNA methylation differences in prefrontal cortex implicates the immune processes in Alzheimer's disease. Nat Commun, 2020. 11 (1): p. 6114. Lehrer, S. and P.H. Rheinstein, RORB, an Alzheimer's disease susceptibility gene, is associated with viral encephalitis, an Alzheimer's disease risk factor. Clin Neurol Neurosurg, 2023. 233 : p. 107984. Weller, A.E., et al., Single Nucleus Transcriptome Data from Alzheimer's Disease Mouse Models Yield New Insight into Pathophysiology. J Alzheimers Dis, 2022. 90 (3): p. 1233-1247. Liu, F., et al., A genomewide screen for late-onset Alzheimer disease in a genetically isolated Dutch population. Am J Hum Genet, 2007. 81 (1): p. 17-31. Brenes, A.J., et al., Erosion of human X chromosome inactivation causes major remodeling of the iPSC proteome. Cell Rep, 2021. 35 (4): p. 109032. Liao, W., et al., Identification of candidate genes associated with clinical onset of Alzheimer's disease. Front Neurosci, 2022. 16 : p. 1060111. Hartl, D., et al., A rare loss-of-function variant of ADAM17 is associated with late-onset familial Alzheimer disease. Mol Psychiatry, 2020. 25 (3): p. 629-639. Blanchard, J.W., et al., APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes. Nature, 2022. 611 (7937): p. 769-779. Radanovic, M., et al., White matter abnormalities associated with Alzheimer's disease and mild cognitive impairment: a critical review of MRI studies. Expert Rev Neurother, 2013. 13 (5): p. 483-93. Butt, A.M., I.C. De La Rocha, and A. Rivera, Oligodendroglial Cells in Alzheimer's Disease. Adv Exp Med Biol, 2019. 1175 : p. 325-333. Kao, Y.H., et al., White Matter Changes in Patients with Alzheimer's Disease and Associated Factors. J Clin Med, 2019. 8 (2). Dean, D.C., 3rd, et al., Brain differences in infants at differential genetic risk for late-onset Alzheimer disease: a cross-sectional imaging study. JAMA Neurol, 2014. 71 (1): p. 11-22. Remer, J., et al., Longitudinal white matter and cognitive development in pediatric carriers of the apolipoprotein epsilon4 allele. Neuroimage, 2020. 222 : p. 117243. Vance, J.M., et al., Report of the APOE4 National Institute on Aging/Alzheimer Disease Sequencing Project Consortium Working Group: Reducing APOE4 in Carriers is a Therapeutic Goal for Alzheimer's Disease. Ann Neurol, 2024. Kuhn, S., et al., Oligodendrocytes in Development, Myelin Generation and Beyond. Cells, 2019. 8 (11). Beiter, R.M., et al., Evidence for oligodendrocyte progenitor cell heterogeneity in the adult mouse brain. Sci Rep, 2022. 12 (1): p. 12921. Yun, W., et al., OCT4-induced oligodendrocyte progenitor cells promote remyelination and ameliorate disease. NPJ Regen Med, 2022. 7 (1): p. 4. Zou, P., et al., Oligodendrocyte progenitor cells in Alzheimer's disease: from physiology to pathology. Transl Neurodegener, 2023. 12 (1): p. 52. Vanzulli, I., et al., Disruption of oligodendrocyte progenitor cells is an early sign of pathology in the triple transgenic mouse model of Alzheimer's disease. Neurobiol Aging, 2020. 94 : p. 130-139. Suchy-Dicey, A., et al., APOE genotype, hippocampus, and cognitive markers of Alzheimer's disease in American Indians: Data from the Strong Heart Study. Alzheimers Dement, 2022. 18 (12): p. 2518-2526. Belloy, M.E., et al., APOE Genotype and Alzheimer Disease Risk Across Age, Sex, and Population Ancestry. JAMA Neurol, 2023. 80 (12): p. 1284-1294. Supplementary Files Supplementaryfile1OPCDEGs.xlsx Supplementary_file_1_OPC_DEGs: Table S1. Differentially expressed genes in OPCs of AF GA compared to AI GA. Table S2. Differentially expressed genes in OPCs of EU GA compared to AI GA. Table S3.Differentially expressed genes in OPCs of EU GA compared to AF GA. Table S4.Differentially expressed genes in OPCs from AI Males compared to AI Females. Supplementaryfile2OLsDEGs.xlsx Supplementary_file_2_OL_DEGs: Table S5. Differentially expressed genes in OLs of AF GA compared to AI GA. Table S6. Differentially expressed genes in OLs of EU GA compared to AI GA. Table S7. Differentially expressed genes in OLs of EU GA compared to AF GA. Table S8. Differentially expressed genes in OLs from AI Males compared to AI Females. Supplementaryfile3OPCDAPsDAGs.xlsx Supplementary_file_3_OPC_DAPs-DAGs: Table S9. Differentially accessible chromatin in OPCs of AF GA compared to AI GA. Table S10. Differentially accessible chromatin in OPCs of EU GA compared to AI GA. Table S11.Differentially accessible chromatin in OPCs of EU GA compared to AF GA. Table S12. Differentially accessible chromatin in OPCs from AI Males compared to AI Females. Supplementaryfile4OLDAPsDAGs.xlsx Supplementary_file_4_OL_DAPs-DAGs: Table S13. Differentially accessible chromatin in OLs of AF GA compared to AI GA. Table S14. Differentially accessible chromatin in OLs of EU GA compared to AI GA. Table S15. Differentially accessible chromatin in OLs of EU GA compared to AF GA. Table S16. Differentially accessible chromatin in OLs from AI Males compared to AI Females. Supplemetaryfile5DEGsAPOEADSTATUS.xlsx Supplementary_file _5_DEGs_APOE_AD_STATUS: Table S17. Differentially expressed genes in OPCs from APOE3/3 carriers compared to APOE4/4 carriers. Table S18. Differentially expressed genes in OLs from APOE3/3 carriers compared to APOE4/4 carriers. Table S19. Differentially expressed genes in OPCs from AD patients compared to NCI controls. Table S20. Differentially expressed genes in OLs from AD patients compared to NCI controls. Supplementaryfile6OPCDAPsDAGs.xlsx Supplementary_file _5_DEGs_APOE_AD_STATUS: Table S17. Differentially expressed genes in OPCs from APOE3/3 carriers compared to APOE4/4 carriers. Table S18. Differentially expressed genes in OLs from APOE3/3 carriers compared to APOE4/4 carriers. Table S19. Differentially expressed genes in OPCs from AD patients compared to NCI controls. Table S20. Differentially expressed genes in OLs from AD patients compared to NCI controls. GraphicalAbstract.pdf Supplementoryfig1.png Supplementary Figure S1. Visualization of single nuclei clusters from 47,898 nuclei integrated across 12 samples of iPS-derived neural 3D cultures including 4 samples from each ancestry (AF, AI, EU) A. Clustering of single nuclei from the integrated datasets representing the identified cellular clusters based on scRNA-seq data. Supplementoryfig2.png Supplementary figure S2. Visualization of single nuclei clusters from 47,898 nuclei integrated across 4 samples of iPS-derived 3D neural spheroids in the different ancestries (AF, AI, EU). Clustering of single nuclei from the integrated datasets representing the identified cellular clusters based on scRNA-seq data for the different ancestries. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-5338140","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":378696349,"identity":"939ea105-9328-4be3-a07a-c8c8979c8bbf","order_by":0,"name":"Aura M Ramirez","email":"","orcid":"","institution":"University of Miami Miller School of Medicine: University of Miami School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Aura","middleName":"M","lastName":"Ramirez","suffix":""},{"id":378696350,"identity":"5832b056-3ec0-4821-acbb-4785f95eaa9a","order_by":1,"name":"Luciana Bertholim-Nasciben","email":"","orcid":"","institution":"University of Miami Miller School of Medicine: University of Miami School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Luciana","middleName":"","lastName":"Bertholim-Nasciben","suffix":""},{"id":378696351,"identity":"b26c9766-dd36-4d56-9fcd-b32a81fd20e3","order_by":2,"name":"Sofia Moura","email":"","orcid":"","institution":"University of Miami Miller School of Medicine: University of Miami School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Sofia","middleName":"","lastName":"Moura","suffix":""},{"id":378696352,"identity":"e931b2a1-ab49-4dd1-91aa-f69b422cacf5","order_by":3,"name":"Lauren E Coombs","email":"","orcid":"","institution":"University of Miami Miller School of Medicine: University of Miami School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Lauren","middleName":"E","lastName":"Coombs","suffix":""},{"id":378696353,"identity":"f3df0573-af23-4cda-838b-58743b65b725","order_by":4,"name":"Farid Rajabli","email":"","orcid":"","institution":"University of Miami Miller School of Medicine: University of Miami School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Farid","middleName":"","lastName":"Rajabli","suffix":""},{"id":378696354,"identity":"b922daba-c230-4ca2-80fb-ea1b0f3e68a2","order_by":5,"name":"Brooke A. DeRosa","email":"","orcid":"","institution":"University of Miami Miller School of Medicine: University of Miami School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Brooke","middleName":"A.","lastName":"DeRosa","suffix":""},{"id":378696355,"identity":"b83ff4ed-1b37-45ef-94ac-055feefcc0fe","order_by":6,"name":"Patrice G Whitehead","email":"","orcid":"","institution":"University of Miami Miller School of Medicine: University of Miami School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Patrice","middleName":"G","lastName":"Whitehead","suffix":""},{"id":378696356,"identity":"e8308f35-57bf-474c-b562-0f9aa6e08db9","order_by":7,"name":"Larry D Adams","email":"","orcid":"","institution":"University of Miami Miller School of Medicine: University of Miami School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Larry","middleName":"D","lastName":"Adams","suffix":""},{"id":378696357,"identity":"1915a7b3-eac3-471a-82af-d34e538ded70","order_by":8,"name":"Takiyah D Starks","email":"","orcid":"","institution":"Wake Forest School of Medicine: Wake Forest University School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Takiyah","middleName":"D","lastName":"Starks","suffix":""},{"id":378696358,"identity":"6441bc24-6cea-4b27-85fc-ac35f37e9723","order_by":9,"name":"Pedro Mena","email":"","orcid":"","institution":"University of Miami Miller School of Medicine: University of Miami School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Pedro","middleName":"","lastName":"Mena","suffix":""},{"id":378696359,"identity":"0f42b42e-bf6b-45ad-9f62-a53f78b13caa","order_by":10,"name":"Maryenela Illannes-Manrique","email":"","orcid":"","institution":"Global Brain Health Institute","correspondingAuthor":false,"prefix":"","firstName":"Maryenela","middleName":"","lastName":"Illannes-Manrique","suffix":""},{"id":378696360,"identity":"5ba34c24-1772-47f5-bdc0-d2761e0a6d62","order_by":11,"name":"Sergio J Tejada","email":"","orcid":"","institution":"University of Miami Miller School of Medicine: University of Miami School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Sergio","middleName":"J","lastName":"Tejada","suffix":""},{"id":378696361,"identity":"3ab4388f-8cbf-433c-a398-79dcbff78c1e","order_by":12,"name":"Goldie S Byrd","email":"","orcid":"","institution":"Wake Forest School of Medicine: Wake Forest University School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Goldie","middleName":"S","lastName":"Byrd","suffix":""},{"id":378696362,"identity":"765a9af6-1a46-42c6-82cc-0d93e721fc31","order_by":13,"name":"Allison Caban-Holt","email":"","orcid":"","institution":"Wake Forest School of Medicine: Wake Forest University School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Allison","middleName":"","lastName":"Caban-Holt","suffix":""},{"id":378696363,"identity":"a3442fd1-ad0e-4a73-be6f-a5aa318fffcd","order_by":14,"name":"Michael Cuccaro","email":"","orcid":"","institution":"University of Miami Miller School of Medicine: University of Miami School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Michael","middleName":"","lastName":"Cuccaro","suffix":""},{"id":378696364,"identity":"2a5f9f67-3e34-4cd9-8955-c924d252cbfa","order_by":15,"name":"Katalina McInerney","email":"","orcid":"","institution":"University of Miami Miller School of Medicine: University of Miami School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Katalina","middleName":"","lastName":"McInerney","suffix":""},{"id":378696365,"identity":"f27f6ce1-7203-4d2c-8a5c-24af16322194","order_by":16,"name":"Mario Cornejo-Olivas","email":"","orcid":"","institution":"Universidad Científica del Sur Facultad de Ciencias de la Salud: Universidad Cientifica del Sur Facultad de Ciencias de la Salud","correspondingAuthor":false,"prefix":"","firstName":"Mario","middleName":"","lastName":"Cornejo-Olivas","suffix":""},{"id":378696366,"identity":"cdf3cd77-5823-4151-b85c-909038a5d195","order_by":17,"name":"Briseida Feliciano-Astacio","email":"","orcid":"","institution":"Universidad Central Del Caribe Escuela De Medicina: Universidad Central del Caribe School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Briseida","middleName":"","lastName":"Feliciano-Astacio","suffix":""},{"id":378696367,"identity":"9aac48be-7753-4435-b5a3-5aa5da8d7ec0","order_by":18,"name":"Liyong Wang","email":"","orcid":"","institution":"University of Miami Miller School of Medicine: University of Miami School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Liyong","middleName":"","lastName":"Wang","suffix":""},{"id":378696368,"identity":"aec52923-fae6-40bc-93f2-d69e0b5d6a13","order_by":19,"name":"Maria C Robayo","email":"","orcid":"","institution":"University of Miami Miller School of Medicine: University of Miami School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Maria","middleName":"C","lastName":"Robayo","suffix":""},{"id":378696369,"identity":"1467ecbe-82a1-4186-b55f-e683b081e360","order_by":20,"name":"Wanying Xu","email":"","orcid":"","institution":"Case Western Reserve University School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Wanying","middleName":"","lastName":"Xu","suffix":""},{"id":378696370,"identity":"9711a458-4197-4b9f-9c34-6eb9ff8ad105","order_by":21,"name":"Fulai Jin","email":"","orcid":"","institution":"Case Western Reserve University School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Fulai","middleName":"","lastName":"Jin","suffix":""},{"id":378696371,"identity":"81e82815-5595-4cbb-a7aa-26e8a45a7b82","order_by":22,"name":"Margaret A Pericak-Vance","email":"","orcid":"","institution":"University of Miami Miller School of Medicine: University of Miami School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Margaret","middleName":"A","lastName":"Pericak-Vance","suffix":""},{"id":378696372,"identity":"04380af9-4198-4392-80ef-4ebb728048fe","order_by":23,"name":"Anthony J Griswold","email":"","orcid":"","institution":"University of Miami Miller School of Medicine: University of Miami School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Anthony","middleName":"J","lastName":"Griswold","suffix":""},{"id":378696373,"identity":"2ed5e67b-a303-45b8-a619-7012f21fe75f","order_by":24,"name":"Derek M Dykxhoorn","email":"","orcid":"","institution":"University of Miami Miller School of Medicine: University of Miami School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Derek","middleName":"M","lastName":"Dykxhoorn","suffix":""},{"id":378696374,"identity":"bafe671c-0233-41d0-8ee6-3fba0d490a9d","order_by":25,"name":"Juan I Young","email":"","orcid":"","institution":"University of Miami Miller School of Medicine: University of Miami School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Juan","middleName":"I","lastName":"Young","suffix":""},{"id":378696375,"identity":"5a5cea2d-d0bd-48ed-ab26-8f8250691ae3","order_by":26,"name":"Jeffery M Vance","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA30lEQVRIiWNgGAWjYBACxgYwZQPECWDEA2QZEKMljQQtUHAYogUK8GthnpH87MGPivPR/OwJrBse1GyTYWBv3iaB12Ez0swNe87czp3Z84DtRsKx2zwMPMfK8GvpOWAmzdh2O3fDjQSgFjagFokcMwJajn+TZvx3Lnc/WMs/oBb5NwS0tPcAbWk4kLtBAqglsQ1kCw9BLWWSPceSc2ecedh2I7HvNg8bT1qxBT4ths3s2yR+1Njl9rcnH7v549tte372wxtv4NXSgLAQwmTDpxwE5AkpGAWjYBSMglHAAABeUkv1q5M3gQAAAABJRU5ErkJggg==","orcid":"https://orcid.org/0000-0003-3815-8199","institution":"University of Miami Miller School of Medicine: University of Miami School of Medicine","correspondingAuthor":true,"prefix":"","firstName":"Jeffery","middleName":"M","lastName":"Vance","suffix":""}],"badges":[],"createdAt":"2024-10-26 15:14:39","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-5338140/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-5338140/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":70588352,"identity":"e90d1a6b-59bf-48d6-9ab3-7fde582002f2","added_by":"auto","created_at":"2024-12-04 16:20:17","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":628776,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eCharacterization of iPSC-derived neural spheroids with different ancestral backgrounds. A.\u003c/strong\u003e Representative image of immunocytochemistry analysis of iPSC derived neural 3D cultures. \u003cstrong\u003eB.\u003c/strong\u003eVisualization of single nuclei clusters from 47,898 nuclei integrated across 12 samples of iPS-derived neural 3D cultures including 4 samples from each ancestry (AF, AI, EU).Clustering of single nuclei from the integrated datasets representing the identified cellular clusters based on scRNA-seq data and grouped by cell type. \u003cstrong\u003eC.\u003c/strong\u003e Visualization of different cell marker expression in the different cell clusters shown in B. Cells are Expression depicted from purple (low) to yellow (high).\u003c/p\u003e","description":"","filename":"1.png","url":"https://assets-eu.researchsquare.com/files/rs-5338140/v1/f939ffff533533988a866629.png"},{"id":70589130,"identity":"0a25e2b4-803b-410b-8737-85a4aac7ccb5","added_by":"auto","created_at":"2024-12-04 16:28:17","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":195083,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eAncestry-Related Transcriptomic Changes in Oligodendroglia. \u003c/strong\u003eVolcano plots illustrating differential gene expression analyses for oligodendroglia clusters, specifically Oligodendrocyte Progenitor Cells (OPC) and mature Oligodendrocytes, across diverse ancestry backgrounds. Each plot represents a pairwise comparison of ancestry groups, highlighting the number of differentially expressed genes (DEGs). \u003cstrong\u003eA. \u003c/strong\u003eEuropean vs. Amerindian comparison in the OPC cluster\u003cstrong\u003e. B.\u003c/strong\u003e European vs. Amerindian comparison in the Oligodendrocyte. \u003cstrong\u003eC.\u003c/strong\u003e African vs. Amerindian comparison in the OPC cluster. \u003cstrong\u003eD. \u003c/strong\u003eAfrican vs. Amerindian comparison in the Oligodendrocyte cluster. \u003cstrong\u003eE. \u003c/strong\u003eEuropean vs. African comparison in the OPC cluster\u003cstrong\u003e. F. \u003c/strong\u003eEuropean vs. African comparison in the Oligodendrocyte cluster.\u003c/p\u003e","description":"","filename":"2.png","url":"https://assets-eu.researchsquare.com/files/rs-5338140/v1/f1518c244608e957839e8ab4.png"},{"id":70589129,"identity":"6d0bbf92-0ff1-4d98-8ca0-798e702243f1","added_by":"auto","created_at":"2024-12-04 16:28:17","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":62935,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eAncestry-Dependent Expression of Alzheimer's Disease GWAS Hits and Related Genes in iOPC and iOligodendrocyte Clusters. \u003c/strong\u003eBoxplots showing gene expression differences between \u003cstrong\u003eA.\u003c/strong\u003eoligodendrocyte precursor cells (OPC) and \u003cstrong\u003eB.\u003c/strong\u003e oligodendrocytes (OL) in relation to Alzheimer's disease (AD) and ancestry-dependent changes.\u003c/p\u003e","description":"","filename":"3.png","url":"https://assets-eu.researchsquare.com/files/rs-5338140/v1/a4e56ee04f7e5c0fc42a7272.png"},{"id":70589128,"identity":"b37b8af6-2030-4168-ab58-075e108b32a4","added_by":"auto","created_at":"2024-12-04 16:28:17","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":207006,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eTranscriptional Changes in Oligodendroglia Based on APOE Genotype. \u003c/strong\u003eDifferential gene expression occurring in oligodendroglia based on \u003cem\u003eAPOE\u003c/em\u003e genotype, comparing the \u003cem\u003eAPOE3/3\u003c/em\u003elines to the \u003cem\u003eAPOE4/4 lines\u003c/em\u003e, irrespective of their ancestry. \u003cstrong\u003eA. \u003c/strong\u003eVolcano plot showing DEGs between \u003cem\u003eAPOE3/3\u003c/em\u003e and \u003cem\u003eAPOE4/4\u003c/em\u003e samples in the iOPC cluster. Genes that have been reported as AD GWAS hits are labeled. \u003cstrong\u003eB. \u003c/strong\u003eDot plot illustrating the pseudo-bulk expression of the differentially expressed AD GWAS hits in the iOPC cluster. \u003cstrong\u003eC. \u003c/strong\u003eVolcano plot showing DEGs between \u003cem\u003eAPOE3/3\u003c/em\u003eand \u003cem\u003eAPOE4/4\u003c/em\u003e samples in the iOL cluster. Genes that have been reported as AD GWAS hits are labeled. \u003cstrong\u003eD. \u003c/strong\u003eDot plot illustrating the pseudo-bulk expression of the differentially expressed AD GWAS hits in the iOL cluster.\u003c/p\u003e","description":"","filename":"4.png","url":"https://assets-eu.researchsquare.com/files/rs-5338140/v1/2a9b3576fa617e99bd7f1aaa.png"},{"id":70588356,"identity":"7c694ca8-b862-40a8-9b70-4a40cf203bb3","added_by":"auto","created_at":"2024-12-04 16:20:17","extension":"png","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":246865,"visible":true,"origin":"","legend":"\u003cp\u003ePathway analysis of DEGs found in oligodendroglia when compared by \u003cem\u003eAPOE\u003c/em\u003e genotype and AD status \u003cstrong\u003eA.\u003c/strong\u003ePathways enriched in OPCs from APOE4/4 carriers compared to APOE3/3 carriers. \u003cstrong\u003eB. \u003c/strong\u003ePathways enriched in iOLs from \u003cem\u003eAPOE4/4\u003c/em\u003e carriers compared to \u003cem\u003eAPOE3/3\u003c/em\u003ecarriers iOPC. \u003cstrong\u003eC.\u003c/strong\u003e Pathways enriched in iOPCs from AD compared to NCI. \u003cstrong\u003eD.\u003c/strong\u003e Pathways enriched in iOLs from AD compared to NCI.\u003c/p\u003e","description":"","filename":"5.png","url":"https://assets-eu.researchsquare.com/files/rs-5338140/v1/263ed1313bf897ed26630d6d.png"},{"id":70588353,"identity":"989103e5-39b4-4efe-904d-d110fed427e7","added_by":"auto","created_at":"2024-12-04 16:20:17","extension":"png","order_by":6,"title":"Figure 6","display":"","copyAsset":false,"role":"figure","size":92829,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eDifferential expression of genes implicated in cholesterol biosynthesis and myelination between iPSC derived OPCs with different \u003c/strong\u003e\u003cem\u003e\u003cstrong\u003eAPOE\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003e genotypes. \u003c/strong\u003eDot plot illustrates the pseudo-bulk expression of the differentially expressed genes (p_val_adj\u0026lt;0.05 and Fold change \u0026gt;1 or \u0026lt;-1)\u003c/p\u003e","description":"","filename":"6.png","url":"https://assets-eu.researchsquare.com/files/rs-5338140/v1/bb70d5696ff6686f9949deba.png"},{"id":70588370,"identity":"da62b85e-5052-40f8-a4d6-821a140a4c4b","added_by":"auto","created_at":"2024-12-04 16:20:18","extension":"png","order_by":7,"title":"Figure 7","display":"","copyAsset":false,"role":"figure","size":305639,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003ePathway analysis for DEGs Across Ancestries. \u003c/strong\u003eDEGs found for each pairwise ancestry comparison in both oligodendroglia clusters were used for pathway analysis. \u003cstrong\u003eA\u003c/strong\u003e. Pathways enriched between AF and AI iOPCs. \u003cstrong\u003eB. \u003c/strong\u003ePathways enriched between AF and AI iOLs. \u003cstrong\u003eC. \u003c/strong\u003ePathways enriched between EU and AI iOPCs. \u003cstrong\u003eD. \u003c/strong\u003ePathways enriched between EU and AI iOLs. \u003cstrong\u003eE. \u003c/strong\u003ePathways enriched between EU and AI OPCs\u003c/p\u003e","description":"","filename":"7.png","url":"https://assets-eu.researchsquare.com/files/rs-5338140/v1/42c85e1bbf70db3cb1a8874f.png"},{"id":70589470,"identity":"4bd3fda1-b25b-4398-8bb8-0fcba0447956","added_by":"auto","created_at":"2024-12-04 16:36:17","extension":"png","order_by":8,"title":"Figure 8","display":"","copyAsset":false,"role":"figure","size":606671,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eVisualization of single nuclei clusters from 76409 nuclei integrated across 12 samples of iPS-derived neural 3D cultures including 4 samples from each ancestry (AF, AI, EU) A. \u003c/strong\u003eClustering of single nuclei from the integrated datasets representing the identified cellular clusters based on ATAC-seq data. \u003cstrong\u003eB. \u003c/strong\u003eVisualization of oligodendroglia markers expression in the different cell clusters shown in A. Accessibility depicted from purple (low) to yellow (high).\u003c/p\u003e","description":"","filename":"8.png","url":"https://assets-eu.researchsquare.com/files/rs-5338140/v1/f79a3b85f23840de5d49998f.png"},{"id":70589134,"identity":"cb1fcdfd-08e6-4685-96c7-308487dd3c8c","added_by":"auto","created_at":"2024-12-04 16:28:17","extension":"png","order_by":9,"title":"Figure 9","display":"","copyAsset":false,"role":"figure","size":214724,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eAncestry-Related Chromatin Accessibility Changes in Oligodendroglia. \u003c/strong\u003eVolcano plots illustrating differential chromatin accessibility across different ancestral backgrounds in oligodendroglia clusters, specifically iOPC and mature iOligodendrocytes. Each plot represents a pairwise comparison of ancestry groups, highlighting the genes with differentially accessible chromatin. \u003cstrong\u003eA.\u003c/strong\u003e African vs. Amerindian comparison in the iOPC cluster \u003cstrong\u003eB.\u003c/strong\u003e European vs. Amerindian comparison in the iOL. \u003cstrong\u003e(C)\u003c/strong\u003e African vs. European comparison in the iOPC cluster \u003cstrong\u003eD. \u003c/strong\u003eAfrican vs. Amerindian comparison in the iOL cluster. \u003cstrong\u003eE.\u003c/strong\u003eEuropean vs. Amerindian comparison in the OPC cluster. \u003cstrong\u003eF. \u003c/strong\u003eEuropean vs. African comparison in the Oligodendrocyte cluster.\u003c/p\u003e","description":"","filename":"9.png","url":"https://assets-eu.researchsquare.com/files/rs-5338140/v1/4a88d1d23a6bced28169cabf.png"},{"id":70588357,"identity":"795e9990-c192-458b-81fe-d7d3b39a9f18","added_by":"auto","created_at":"2024-12-04 16:20:17","extension":"png","order_by":10,"title":"Figure 10","display":"","copyAsset":false,"role":"figure","size":204798,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eComparison of Differentially Accessible Genes and Differentially Expressed Genes. \u003c/strong\u003eVenn Diagram Analysis showing the overlap between differentially accessible genes, differentially expressed genes, and AD GWAS hits for the different pairwise comparisons made based on global ancestry for the OPC (\u003cstrong\u003eA, B and C\u003c/strong\u003e) and the OL (\u003cstrong\u003eD, E and F\u003c/strong\u003e) clusters.\u003c/p\u003e","description":"","filename":"10.png","url":"https://assets-eu.researchsquare.com/files/rs-5338140/v1/f29ee53282efe9ec12c6cae2.png"},{"id":70588365,"identity":"23da7dfd-b28b-47ce-b356-f357c07d1404","added_by":"auto","created_at":"2024-12-04 16:20:17","extension":"png","order_by":11,"title":"Figure 11","display":"","copyAsset":false,"role":"figure","size":256591,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eChromatin accessibility and Hi-C loops overview for a subregion of \u003c/strong\u003e\u003cem\u003e\u003cstrong\u003eFGF12\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003e in oligodendroglia of different ancestries\u003c/strong\u003e. Highlighted in yellow is a DAP between ancestries with a profile that correlates with \u003cem\u003eFGF12\u003c/em\u003e expression.\u003c/p\u003e","description":"","filename":"11.png","url":"https://assets-eu.researchsquare.com/files/rs-5338140/v1/d290498a9ffe33d3d5b3637b.png"},{"id":70589133,"identity":"fa79300e-821a-4c82-ab8e-bcb5a7b05bf4","added_by":"auto","created_at":"2024-12-04 16:28:17","extension":"png","order_by":12,"title":"Figure 12","display":"","copyAsset":false,"role":"figure","size":226646,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eComparative analysis of differentially expressed genes (DEGs) and genes with differentially accessible peaks (DAPs) in oligodendroglia based on APOE genotype. A-B. \u003c/strong\u003eComparison of \u003cem\u003eAPOE3/3\u003c/em\u003e OPCs to \u003cem\u003eAPOE4/4\u003c/em\u003e OPCs. \u003cstrong\u003eC-D \u003c/strong\u003eComparison of \u003cem\u003eAPOE3/3\u003c/em\u003eOligodendrocytes to \u003cem\u003eAPOE4/4\u003c/em\u003e Oligodendrocytes.\u003c/p\u003e","description":"","filename":"12.png","url":"https://assets-eu.researchsquare.com/files/rs-5338140/v1/ef9e1e5acc108e5d1c3f7372.png"},{"id":70588367,"identity":"7ee777de-49c9-43ea-a126-858bb069416a","added_by":"auto","created_at":"2024-12-04 16:20:17","extension":"png","order_by":13,"title":"Figure 13","display":"","copyAsset":false,"role":"figure","size":208565,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eComparative analysis of differentially expressed genes (DEGs) and genes with differentially accessible peaks (DAPs) in oligodendroglia based on Alzheimer’s disease status. A-B. \u003c/strong\u003eComparison of OPCs from affected donors to non-cognitively impaired donors OPCs. \u003cstrong\u003eC-D \u003c/strong\u003eComparison of Oligodendrocytes from affected donors to Oligodendrocytes from unaffected controls.\u003c/p\u003e","description":"","filename":"13.png","url":"https://assets-eu.researchsquare.com/files/rs-5338140/v1/054f37c3fd142d2c0c62762f.png"},{"id":71062188,"identity":"3e24e2bb-9e1f-4493-be07-25999c0f1e33","added_by":"auto","created_at":"2024-12-10 17:41:21","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":4926855,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-5338140/v1/7e3b577a-27a0-4042-b84e-9721ffba8c39.pdf"},{"id":70588366,"identity":"7fc54b30-912a-4812-9c5b-de70f45bb504","added_by":"auto","created_at":"2024-12-04 16:20:17","extension":"xlsx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":3644642,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eSupplementary_file_1_OPC_DEGs: Table S1. \u003c/strong\u003eDifferentially expressed genes in OPCs of AF GA compared to AI GA. \u003cstrong\u003eTable S2. \u003c/strong\u003eDifferentially expressed genes in OPCs of EU GA compared to AI GA. \u003cstrong\u003eTable S3.\u003c/strong\u003eDifferentially expressed genes in OPCs of EU GA compared to AF GA. \u003cstrong\u003eTable S4.\u003c/strong\u003eDifferentially expressed genes in OPCs from AI Males compared to AI Females.\u003c/p\u003e","description":"","filename":"Supplementaryfile1OPCDEGs.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-5338140/v1/56580dcb72b945bace8bcf59.xlsx"},{"id":70589131,"identity":"837edaa8-2848-43ab-815b-f59073f4f4d1","added_by":"auto","created_at":"2024-12-04 16:28:17","extension":"xlsx","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":3491107,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eSupplementary_file_2_OL_DEGs: Table S5. \u003c/strong\u003eDifferentially expressed genes in OLs of AF GA compared to AI GA. \u003cstrong\u003eTable S6. \u003c/strong\u003eDifferentially expressed genes in OLs of EU GA compared to AI GA. \u003cstrong\u003eTable S7.\u003c/strong\u003e Differentially expressed genes in OLs of EU GA compared to AF GA. \u003cstrong\u003eTable S8.\u003c/strong\u003e Differentially expressed genes in OLs from AI Males compared to AI Females.\u003c/p\u003e","description":"","filename":"Supplementaryfile2OLsDEGs.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-5338140/v1/399d96bbc31b36a9a6b6a55a.xlsx"},{"id":70588375,"identity":"35a1837d-2368-4b29-b571-a51c552885d8","added_by":"auto","created_at":"2024-12-04 16:20:23","extension":"xlsx","order_by":3,"title":"","display":"","copyAsset":false,"role":"supplement","size":261268267,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eSupplementary_file_3_OPC_DAPs-DAGs: Table S9. \u003c/strong\u003eDifferentially accessible chromatin in OPCs of AF GA compared to AI GA. \u003cstrong\u003eTable S10. \u003c/strong\u003eDifferentially accessible chromatin in OPCs of EU GA compared to AI GA. \u003cstrong\u003eTable S11.\u003c/strong\u003eDifferentially accessible chromatin in OPCs of EU GA compared to AF GA. \u003cstrong\u003eTable S12.\u003c/strong\u003e Differentially accessible chromatin in OPCs from AI Males compared to AI Females.\u003c/p\u003e","description":"","filename":"Supplementaryfile3OPCDAPsDAGs.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-5338140/v1/71ef681d8a9fd08a1ffb31ce.xlsx"},{"id":70588377,"identity":"83ec8e09-af09-49dc-aeaa-212ea11bf814","added_by":"auto","created_at":"2024-12-04 16:20:24","extension":"xlsx","order_by":4,"title":"","display":"","copyAsset":false,"role":"supplement","size":248273353,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eSupplementary_file_4_OL_DAPs-DAGs: Table S13. \u003c/strong\u003eDifferentially accessible chromatin in OLs of AF GA compared to AI GA. \u003cstrong\u003eTable S14. \u003c/strong\u003eDifferentially accessible chromatin in OLs of EU GA compared to AI GA. \u003cstrong\u003eTable S15.\u003c/strong\u003e Differentially accessible chromatin in OLs of EU GA compared to AF GA. \u003cstrong\u003eTable S16.\u003c/strong\u003e Differentially accessible chromatin in OLs from AI Males compared to AI Females.\u003c/p\u003e","description":"","filename":"Supplementaryfile4OLDAPsDAGs.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-5338140/v1/add1a5d281d21897a80029c9.xlsx"},{"id":70588368,"identity":"77cee26d-298c-4395-9f7c-c767b0559f57","added_by":"auto","created_at":"2024-12-04 16:20:17","extension":"xlsx","order_by":5,"title":"","display":"","copyAsset":false,"role":"supplement","size":3646169,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eSupplementary_file _5_DEGs_APOE_AD_STATUS: Table S17. \u003c/strong\u003eDifferentially expressed genes in OPCs from \u003cem\u003eAPOE3/3\u003c/em\u003e carriers compared to \u003cem\u003eAPOE4/4\u003c/em\u003ecarriers. \u003cstrong\u003eTable S18. \u003c/strong\u003eDifferentially expressed genes in OLs from \u003cem\u003eAPOE3/3\u003c/em\u003ecarriers compared to \u003cem\u003eAPOE4/4\u003c/em\u003e carriers. \u003cstrong\u003eTable S19. \u003c/strong\u003eDifferentially expressed genes in OPCs from AD patients compared to NCI controls. \u003cstrong\u003eTable S20. \u003c/strong\u003eDifferentially expressed genes in OLs from AD patients compared to NCI controls.\u003c/p\u003e","description":"","filename":"Supplemetaryfile5DEGsAPOEADSTATUS.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-5338140/v1/2e3a91886588c93d3e57cf87.xlsx"},{"id":70588378,"identity":"5565787d-b185-46f7-a73b-812b8cf41c2b","added_by":"auto","created_at":"2024-12-04 16:20:25","extension":"xlsx","order_by":6,"title":"","display":"","copyAsset":false,"role":"supplement","size":261808478,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eSupplementary_file _5_DEGs_APOE_AD_STATUS: Table S17. \u003c/strong\u003eDifferentially expressed genes in OPCs from \u003cem\u003eAPOE3/3\u003c/em\u003e carriers compared to \u003cem\u003eAPOE4/4\u003c/em\u003ecarriers. \u003cstrong\u003eTable S18. \u003c/strong\u003eDifferentially expressed genes in OLs from \u003cem\u003eAPOE3/3\u003c/em\u003ecarriers compared to \u003cem\u003eAPOE4/4\u003c/em\u003e carriers. \u003cstrong\u003eTable S19. \u003c/strong\u003eDifferentially expressed genes in OPCs from AD patients compared to NCI controls. \u003cstrong\u003eTable S20. \u003c/strong\u003eDifferentially expressed genes in OLs from AD patients compared to NCI controls.\u003c/p\u003e","description":"","filename":"Supplementaryfile6OPCDAPsDAGs.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-5338140/v1/d132da8971f602a22722226e.xlsx"},{"id":70588364,"identity":"6f9854a4-8ca2-48ac-bbcc-9f29fdfda1e7","added_by":"auto","created_at":"2024-12-04 16:20:17","extension":"pdf","order_by":7,"title":"","display":"","copyAsset":false,"role":"supplement","size":820720,"visible":true,"origin":"","legend":"","description":"","filename":"GraphicalAbstract.pdf","url":"https://assets-eu.researchsquare.com/files/rs-5338140/v1/0dc7beb42eabe46a12631978.pdf"},{"id":70588369,"identity":"48d6fdb1-4318-4d95-9e14-902203c38bf5","added_by":"auto","created_at":"2024-12-04 16:20:18","extension":"png","order_by":8,"title":"","display":"","copyAsset":false,"role":"supplement","size":231499,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eSupplementary Figure S1. \u003c/strong\u003eVisualization of single nuclei clusters from 47,898 nuclei integrated across 12 samples of iPS-derived neural 3D cultures including 4 samples from each ancestry (AF, AI, EU) A. Clustering of single nuclei from the integrated datasets representing the identified cellular clusters based on scRNA-seq data.\u003c/p\u003e","description":"","filename":"Supplementoryfig1.png","url":"https://assets-eu.researchsquare.com/files/rs-5338140/v1/d5eff95b843535c74f1abb28.png"},{"id":70588361,"identity":"064a30b0-124c-4751-b175-7f12332d2658","added_by":"auto","created_at":"2024-12-04 16:20:17","extension":"png","order_by":9,"title":"","display":"","copyAsset":false,"role":"supplement","size":317294,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eSupplementary figure S2. \u003c/strong\u003eVisualization of single nuclei clusters from 47,898 nuclei integrated across 4 samples of iPS-derived 3D neural spheroids in the different ancestries (AF, AI, EU). Clustering of single nuclei from the integrated datasets representing the identified cellular clusters based on scRNA-seq data for the different ancestries.\u003c/p\u003e","description":"","filename":"Supplementoryfig2.png","url":"https://assets-eu.researchsquare.com/files/rs-5338140/v1/932a5da930dfef5b2ee4a62c.png"}],"financialInterests":"","formattedTitle":"Ancestral Genomic Functional Differences in Oligodendroglia: Implications for Alzheimer's Disease","fulltext":[{"header":"BACKGROUND","content":"\u003cp\u003eAlzheimer's disease (AD) is a devastating neurodegenerative disorder characterized by progressive cognitive decline and memory loss. Approximately 11% of people aged\u0026thinsp;\u0026ge;\u0026thinsp;65 years have AD and this percentage increases with age, reaching 13% of people aged 75\u0026ndash;84 years and 33% of people aged 85 years or older. Although age is the strongest risk factor for AD development, genetics plays a critical role in driving AD risk. To date, more than 100 genetic loci have been recognized as predisposing factors for AD through genome-wide association studies (GWAS)[\u003cspan additionalcitationids=\"CR2 CR3 CR4 CR5 CR6 CR7\" citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]. Most of these studies have focused on data acquired from non-Hispanic white individuals, with African, African American, and Hispanic/Latino populations being largely underrepresented [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]. Recently, expanding the representation of these populations in genetic studies has been a growing area of focus, driven in large part by large multicenter collaborations, such as the Alzheimer\u0026rsquo;s Disease Sequencing Project (ADSP) [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]. Both Hispanic/Latino and African American populations are admixed populations. Hispanic/Latino individuals\u0026rsquo; have differing combinations of European, Amerindian, and African ancestry, while African Americans have primarily African and European ancestry. As such, expanding the representation of other genomic compositions in genomic studies is imperative, as there is clear evidence of differences in risk loci and effect sizes of risk alleles shared across populations. For example, the ε4 allele of the apolipoprotein E (\u003cem\u003eAPOE\u003c/em\u003e) gene represents the most prominent genetic susceptibility factor for late-onset AD, exerting the most pronounced effect on East Asian (EA) populations (Japanese), followed by non-Hispanic White (European) populations, with a comparatively smaller effect in populations of African descent [\u003cspan additionalcitationids=\"CR12\" citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]. The mechanisms underlying these differences have been shown to be due to ancestry-specific variations in the genomic regulatory architecture (GRA) of the local ancestry surrounding \u003cem\u003eAPOE\u003c/em\u003e [\u003cspan additionalcitationids=\"CR15\" citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]. Notably, GRA is not only ancestry biased but also cell type specific.\u003c/p\u003e \u003cp\u003eWhile extensive research has focused on the role of neurons in AD pathogenesis, recent evidence suggests that glial cells, including oligodendrocytes, play crucial roles in the etiology of AD. Oligodendrocytes, which are traditionally known for their role in myelinating axons in the central nervous system [\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e], have emerged as key players in AD due to their involvement in various AD-associated pathological processes, including neuroinflammation, oxidative stress, and synaptic dysfunction [\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e]. For example, many AD risk genes such as \u003cem\u003eAPP, ANK3\u003c/em\u003e, \u003cem\u003eBACE1, BIN1, PICALM, PSEN1, and SORT1\u003c/em\u003e are highly expressed in oligodendrocytes. Additionally, phosphorylated tau in gray matter has been associated with white matter abnormalities and demyelination in AD patients, with these abnormalities appearing prior to the onset of clinical AD symptoms [\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e], suggesting the importance of oligodendroglia in AD pathogenesis. For these reasons, we examined and compared the GRA of iPSC-derived oligodendroglia from individuals with significant African (AF), Amerindian (AI), or European (EU) global ancestry. Taken together, our results provide a resource for the AD research community to gain knowledge of genetic factors that may be specific to certain populations, thereby providing a more comprehensive understanding of the disease.\u003c/p\u003e"},{"header":"METHODS","content":"\u003cp\u003e \u003cb\u003eSample collection.\u003c/b\u003e \u003c/p\u003e \u003cp\u003eSamples were obtained through genetic studies of AD in African-Americans (R01AG072547 and U01-AG052410), the Puerto Rico Alzheimer Disease Initiative (PRADI) [\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e, \u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e], and an ongoing study of AD in Peru (R01-AG070864) [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e]. The study was approved by the Institutional Review Boards (IRBs) of the University of Miami and the Universidad Peruana Cayetano Heredia (Lima, Peru). All participants provided informed consent in accordance with the guidelines and regulations of the University of Miami. Cognitive data was obtained on all individuals and was reviewed by a boarded neurologist (J.M.V.), and neuropsychologists (M.C., K.M, A. C-H.) for clinical diagnosis.\u003c/p\u003e \u003cp\u003e \u003cb\u003eInduced pluripotent stem cells (iPSCs).\u003c/b\u003e \u003c/p\u003e \u003cp\u003ePeripheral blood mononuclear cells (PBMCs) were extracted from whole blood using SepMate\u0026trade;-50 tubes with Lymphoprep\u0026trade; media by density gradient centrifugation according to the manufacturer's protocol (STEMCELL Technologies). PBMCs from AD patients or aged-matched nondemented controls were selected based on their global ancestry (\u0026gt;\u0026thinsp;90% European, African or Amerindian) (Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e) to be reprogrammed using the CTS\u0026trade; CytoTune\u0026trade;-iPS 2.1 Sendai Reprogramming Kit (Invitrogen) to generate iPSCs in the Hussman Institute for Human Genomics iPSC Core Facility.\u003c/p\u003e \u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eGlobal ancestry estimation\u003c/h2\u003e \u003cp\u003eThe admixture proportion was calculated using a model-based clustering algorithm within ADMIXTURE software [\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e]. A supervised ADMIXTURE analysis was conducted at K\u0026thinsp;=\u0026thinsp;4, incorporating the 4 reference populations (AI, EU, AF, and EA) from combined reference panels of the Human Genome Diversity Project (HGDP) [\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e, \u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e] and 1000 Genomes Phase 3 [\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e, \u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e].\u003c/p\u003e \u003c/div\u003e\n\u003ch3\u003eDerivation of oligodendrocyte-containing spheroids\u003c/h3\u003e\n\u003cp\u003eThe iPSC-derived oligodendrocytes underwent differentiation following a previously established protocol [\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e] with some minor modifications. Briefly, iPSC lines were cultured on vitronectin-coated plates and maintained in Stemflex\u0026trade; medium until they reached 70\u0026ndash;90% confluency. These cultures were then dissociated into single cells using ACCUTASE\u0026trade;. Once dissociated, the cells were plated on Matrigel\u0026reg;-coated six-well plates at a density ranging from 5^10\u003csup\u003e5\u003c/sup\u003e to 1^10\u003csup\u003e6\u003c/sup\u003e cells per well in StemFlex\u0026trade; medium supplemented with RevitaCell\u0026trade;. The cells were incubated at 37\u0026deg;C with 5% CO\u003csub\u003e2\u003c/sub\u003e for 1\u0026ndash;2 days until colonies with a diameter of approximately 100\u0026ndash;250 \u0026micro;m were formed. Upon reaching the desired size, colonies were induced using Neural Induction Media (NIM) supplemented with SB431542 (10 \u0026micro;M), LDN193189 (250 nM), or retinoic acid (100 nM) for 8 days, with daily complete media changes.\u003c/p\u003e \u003cp\u003eOn day 8, the cells were transitioned to N2 medium (DMEM/F12 with L-glutamine, N2 supplement (1x), non-essential amino acids (NEAA), Penicillin-Streptomycin (PenStrep), and 2-mercaptoethanol) supplemented with retinoic acid (100 nM) and a smoothened agonist (1 \u0026micro;M). The cells were maintained in N2 medium for 4 days, with daily media changes with the addition of fresh supplements. Overconfluent monolayers exhibiting 3D structures were mechanically disrupted in a lattice-like pattern using a scalpel to generate aggregates. The newly formed aggregates were detached from the wells using a cell lifter and plated onto ultralow attachment plates at a 1:2 ratio with N2B27 medium (N2 medium with B27 supplement lacking vitamin A), supplemented with retinoic acid (100 nM) and a smoothened agonist (1 \u0026micro;M). The cells were cultured in N2B27 medium for 8 days, with 2/3 media replacement every other day.\u003c/p\u003e \u003cp\u003eThe cells were subsequently switched to PDGF medium (DMEM/F12 with L-glutamine, N2 supplement (1x), NEAA, PenStrep, 2-mercaptoethanol, PDGFaa (10 ng/ml), IGF-1 (10 ng/ml), HGF (5 ng/ml), NT3 (10 ng/ml), T3 (60 ng/ml), biotin (100 ng/ml), cAMP (1 \u0026micro;M), and insulin 25 \u0026micro;g/ml) with 2/3 media replacement every other day for 10 days. Round aggregates with a diameter ranging from 300 to 800 \u0026micro;m and a golden or brown appearance were selectively harvested and plated onto PLO/Laminin-coated plates at a density of 20 aggregates per well of a 6 well plate, using Glial medium (DMEM/F12 with L-glutamine, N2 supplement, NEAA, PenStrep, 2-mercaptoethanol, HEPES, T3, biotin, cAMP, insulin, ascorbic acid). The aggregates were maintained in the PLO/Laminin plates for 45 days with 2/3 media replacement every other day.\u003c/p\u003e\n\u003ch3\u003eNuclei isolation for 10x Chromium Single-cell Multiome ATAC + Gene Expression\u003c/h3\u003e\n\u003cp\u003eOn day 76 after the induction of differentiation, the cultures were harvested, and nuclear isolation was accomplished following a 10x protocol: \u0026ldquo;Nuclei isolation from complex tissues for single-cell multiome ATAC\u0026thinsp;+\u0026thinsp;gene expression sequencing\u0026rdquo; with minor adjustments. Briefly, the cultures were detached from the plates using ACCUTASE\u0026trade; at 37\u0026deg;C for 5 minutes and then washed with PBS\u0026thinsp;+\u0026thinsp;0.04% BSA. The cell pellet was then resuspended in RDD buffer with DNAse I (0.1 U/\u0026micro;L) and incubated on ice for 5 minutes. After DNAse I treatment, the cells were washed twice with PBS\u0026thinsp;+\u0026thinsp;0.04% BSA. The pellets were subsequently resuspended in NP40 lysis buffer, incubated on ice for 5 minutes, and homogenized using a pellet pestle with a cordless motor. The homogenate was then filtered through a 40 \u0026micro;m strainer and pelleted. Nuclei resuspension buffer was added to the pellet, followed by a 5-minute incubation on ice. The pellet was then resuspended and washed twice with nuclei resuspension buffer. Lysis efficiency was assessed by staining with trypan blue and nuclei counted using the Countess\u0026reg; II FL Automated Cell Counter. After verification that lysis reached\u0026thinsp;\u0026gt;\u0026thinsp;95%, the nuclei were pelleted, resuspended in 0.1X lysis buffer, incubated on ice for 2 minutes, washed once with wash buffer, and resuspended in cold diluted nuclear buffer (1x). The number of nuclei was determined using a Cellometer (Nexcelom). The nuclei were diluted to a concentration of 5,500 nuclei/\u0026micro;L for a target cell recovery of 10,000 nuclei. The diluted nuclei suspensions were used for 10x Chromium Single-cell Multiome ATAC\u0026thinsp;+\u0026thinsp;Gene Expression library preparation according to the manufacturer\u0026rsquo;s protocol.\u003c/p\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003eData analysis\u003c/h2\u003e \u003cdiv id=\"Sec7\" class=\"Section3\"\u003e \u003ch2\u003eRNA-seq\u003c/h2\u003e \u003cp\u003eThe raw RNA-seq data were preprocessed to remove noise, correct for batch effects, and perform quality control checks. Clustering analysis was performed using Seurat's graph-based clustering algorithm to identify distinct cell populations. After clustering, similar nuclei with a final resolution of 0.2 in Seurat were clustered leading to the identification of 11 distinct clusters. Cluster identity was assigned based on the expression of lineage-specific marker genes as follows: 0: Astrocytes; 1: Astrocytes; 2: Excitatory neurons; 3: OPC; 4: Inhibitory neurons; 5: Endothelial; 6: Astrocytes; 7: Cycling progenitors; 8: Oligodendrocytes; 9: Inhibitory neurons; and 10: Excitatory neurons (Supplementary Fig. \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003e). The differential expression of genes (DEGs) between ancestral groups within each cluster was determined using the MAST test, which employs a generalized linear model framework incorporating cell detection rates within replicates and across groups as a covariate [\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e]. DEGs were defined as meeting two criteria: p value adjusted\u0026thinsp;\u0026lt;\u0026thinsp;0.05 and a fold change greater than 1 or less than \u0026minus;\u0026thinsp;1. Compared with other single-nucleus differential expression methods, the MAST test is known for its low error and false discovery rates [\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e].\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003ePathway analysis\u003c/h2\u003e \u003cp\u003eThe R library gprofiler [\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e] was used for functional enrichment analysis. We first selected the gene symbols of down and up regulated genes using adjusted p-value of \u0026lt;\u0026thinsp;0.05, and log2FC\u0026thinsp;\u0026gt;\u0026thinsp;0.32 or \u0026lt; -0.32. The function \u003cem\u003egost\u003c/em\u003e was used to perform the gene set enrichment analysis for each comparison using KEGG pathways database. Multiple comparison correction of enrichment scores was done with the \u0026lsquo;gSCS\u0026rsquo; method and pathways with p-adj\u0026thinsp;\u0026lt;\u0026thinsp;0.05 were considered significant.\u003c/p\u003e \u003c/div\u003e\n\u003ch3\u003eATAC-seq\u003c/h3\u003e\n\u003cp\u003eAnalysis of the snATACseq data was performed using the ArchR software package v1.0.1 [\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e] as previously described [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]. Briefly, clustering of cells was performed with five iterations of latent semantic indexing (LSI) followed by batch correction with Harmony [\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e]. We created pseudobulk replicates combining all EU, AF, and AI samples separately and called peaks for each ancestry within each cluster via the addReproduciblePeakSet function in ArchR via the default parameters of the MACS2 callpeak command v2.2.7.1 [\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e]. Differential accessibility for each peak within each cluster was calculated via ArchR getMarkerFeatures.\u003c/p\u003e\n\u003ch3\u003eATAC peak annotation\u003c/h3\u003e\n\u003cp\u003eThe function annotatePeak from Chipseeker R library [\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e] was used to annotate peaks with the nearest gene and genomic region. The annotation was done at the transcript level using the GENCODE V44 database, with the following priority: \"Promoter\", \"5UTR\", \"3UTR\", \"Exon\", \"Intron\", \"Downstream\", \"Intergenic\u0026rdquo;, and the distance of \u0026plusmn;\u0026thinsp;3 kb from the transcription start sites (TSS) was used to assign a peak to a gene promoter-TSS.\u003c/p\u003e \u003cdiv id=\"Sec11\" class=\"Section2\"\u003e \u003ch2\u003eHi-C\u003c/h2\u003e \u003cp\u003eThe in situ Hi-C libraries were constructed following the protocol outlined by Rao et al. [\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e]. In summary, each library yielded 450\u0026ndash;550\u0026nbsp;million paired-end 150 base pairs reads. Over 270\u0026nbsp;million nonredundant, uniquely mapped, paired end reads were subsequently utilized for further analysis of each library. Contact matrices were created at resolutions of 500 kb, 50 kb, and 5 kb. The Directionality Index (DI) value of 40 kb bins was employed to identify the topologically associated domains (TADs). To accurately map enhancer‒promoter interactions, the HiCorr pipeline was employed to correct for Hi-C bias at the sub-TAD level and identify Hi-C loops [\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e].\u003c/p\u003e \u003c/div\u003e"},{"header":"RESULTS","content":"\u003cdiv id=\"Sec13\" class=\"Section2\"\u003e \u003ch2\u003eGeneration of ancestry-specific iPSCs and iPSC-derived oligodendroglia\u003c/h2\u003e \u003cp\u003eWe generated a total of 12 iPSC lines (four African, four Amerindian, and four European) in this study, of which six were from AD patients and six were from non-cognitively impaired individuals (Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e). In addition, we had four \u003cem\u003eAPOE4/4\u003c/em\u003e carriers and eight \u003cem\u003eAPOE3/3\u003c/em\u003e carriers. We differentiated these 12 lines into neural spheroids producing oligodendrocyte lineage cells at different maturation stages ranging from cycling progenitors through to mature myelinating oligodendrocytes. In addition to oligodendrocyte-related cells, the spheroids contained neurons and astrocytes based on immunocytochemistry (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eA) and snRNA-seq (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eB-\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eC) analyses.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eList iPSC lines used in this study.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"11\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c8\" colnum=\"8\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c9\" colnum=\"9\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c10\" colnum=\"10\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c11\" colnum=\"11\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eHIHG ID​\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eSource\u003csup\u003e1\u003c/sup\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eSex\u003csup\u003e2\u003c/sup\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e\u003cem\u003eAPOE\u003c/em\u003e\u003c/p\u003e \u003cp\u003egenotype\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eGlobal Ancestry\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c6\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eDiagnosis\u003csup\u003e3\u003c/sup\u003e​\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c7\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eAge\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"4\" nameend=\"c11\" namest=\"c8\"\u003e \u003cp\u003eGlobal Ancestry\u003csup\u003e4\u003c/sup\u003e\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c8\"\u003e \u003cp\u003eAI\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c9\"\u003e \u003cp\u003eEU\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c10\"\u003e \u003cp\u003eAF\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c11\"\u003e \u003cp\u003eEA\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e201816444​\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eThis study\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eF\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4/4​\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eAF\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eAD\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e67\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.006\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.050\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0.944\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.000\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e201505672\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eThis study\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eF\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3/3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eAF\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eNCI\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e72\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.000\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.036\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0.964\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.000\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e202001540​\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eThis study\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eF\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3/3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eAF\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eAD\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e84\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.003\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.082\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0.915\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0​.000\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e201917729​\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eThis study\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eF\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3/3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eAF\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eMCI\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e90\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.019\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.046\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0.935\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.000\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e202001087​\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eThis study\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eF\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4/4​\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eAI\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eAD​\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e86\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e1.000\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.000\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0.000\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.000\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e202001079​\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eThis study\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eF\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3/3​\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eAI\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eNCI\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e71\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.920\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.077\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0.000\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.002\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e201917151\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eThis study\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eM\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3/3​\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eAI\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eNCI\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e86\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.955\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.042\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0.000\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.003\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e202001121\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eThis study\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eM\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3/3​\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eAI\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eNCI\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e86\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.963\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.011\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0.013\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.013\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e201806025\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eADRC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eF\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4/4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eEU\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eAD\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.002\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.995\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0.004\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.000\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e201806023\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eADRC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eF\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3/3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eEU\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eNCI\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e70\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.007\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.938\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0.055\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.000\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e201806022\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eADRC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eF\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3/3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eEU\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eNCI\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e65\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.000\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.997\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0.003\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.000\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e201616981\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eThis study\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eF\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4/4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eEU\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eAD\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e76\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.050\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0.886\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c10\"\u003e \u003cp\u003e0.048\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.016\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"11\" nameend=\"c11\" namest=\"c1\"\u003e \u003cp\u003e\u003csup\u003e1\u003c/sup\u003eADRC= Alzheimer's Disease Research Center (UCI)\u003c/p\u003e \u003cp\u003e\u003csup\u003e2\u003c/sup\u003eF=Female ; M\u0026thinsp;=\u0026thinsp;Male\u003c/p\u003e \u003cp\u003e\u003csup\u003e3\u003c/sup\u003eAD=Alzheimer\u0026rsquo;s disease ; NCI\u0026thinsp;=\u0026thinsp;Non-Cognitively Impaired ; MCI\u0026thinsp;=\u0026thinsp;Mild cognitive impairment\u003c/p\u003e \u003cp\u003e\u003csup\u003e4\u003c/sup\u003eGlobal ancestry was calculated using admixture software. Refer to Methods for more details.\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003eSingle-nuclei transcriptional profiling of iPSC-derived oligodendroglia containing neural spheroids across diverse ancestries.\u003c/b\u003e \u003c/p\u003e \u003cp\u003eAttempts to isolate individual cell types from the tightly clustered spheroids via FACS or pull-down procedures resulted in a low yield of viable cells. To overcome these difficulties in recovery and minimize the manipulation of the cells, single-nuclei approaches were used to analyze the transcriptional states of the cells in these oligodendrocyte-enriched neural spheroids. These analyses were performed across the 12 iPSC lines from the three ancestral populations. We characterized a total of 47,898 cells, with an average of 3,991\u0026thinsp;\u0026plusmn;\u0026thinsp;1,608 per sample. Seurat-based pattern recognition clustering identified seven cell clusters shared by all the individual samples (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eB and Supplementary Fig. \u003cspan refid=\"MOESM2\" class=\"InternalRef\"\u003eS2\u003c/span\u003e). We subsequently detected genes that were enriched in each cluster and utilized these for the assignment of cell types to each individual cluster. We identified one OPC cluster (enriched for the expression of \u003cem\u003ePDGFRA\u003c/em\u003e, \u003cem\u003eCOL20A1, OLIG1, OLIG2, and PTPRZ1\u003c/em\u003e) (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eB-\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eC) and one oligodendrocyte (OL) cluster (\u003cem\u003eMOG, CLDN11, ENPP6, MYRF, and MBP)\u003c/em\u003e (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eA-\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eB) among other cell types, including astrocytes, excitatory and inhibitory neurons, endothelial cells, and cycling progenitors.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec14\" class=\"Section2\"\u003e \u003ch2\u003eDifferentially expressed genes (DEG) between ancestries\u003c/h2\u003e \u003cp\u003eTo investigate ancestry-related changes in the transcriptome of the oligodendroglia found in our cultures, we performed differential gene expression analyses using pairwise comparisons of the OPC and oligodendrocyte clusters independently (shown in Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003e and Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e). In the OPC cluster, we found that the number of DEGs was greatest in the European vs. Amerindian comparisons, with a total of 1,750 DEGs (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eA, Tables\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e and S1) and approximately 90% (1,573) were increased in the European samples. On the other hand, in the OL cluster, the greatest number of DEGs was found between the African and Amerindian lines, with 492 DEGs, of which\u0026thinsp;~\u0026thinsp;87% (427), were increased in the African lines (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eD, Tables\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e and S4). To identify DEGs common to the oligodendroglia lineage, we analyzed the data to identify overlapping DEGs in both clusters for each comparison (shown in Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eDifferentially expressed genes (DEGs) across ancestries. Total number of DEGs found in each pairwise comparison between different ancestries.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"7\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colspan=\"6\" nameend=\"c7\" namest=\"c2\"\u003e \u003cp\u003eTOTAL GENES (AD GWAS)\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003eiOPC\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003eiOL\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003eiOPC \u0026cap; iOL\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eEU\u0026thinsp;\u0026gt;\u0026thinsp;AI\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1573(8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e1750\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e290(3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e345\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e208(0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e246\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAI\u0026thinsp;\u0026gt;\u0026thinsp;EU\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e177(1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e55(0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e38(0)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAF\u0026thinsp;\u0026gt;\u0026thinsp;AI\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1007(6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e1209\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e427(2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e492\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e250(0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e297\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAI\u0026thinsp;\u0026gt;\u0026thinsp;AF\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e202(3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e65(0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e47(0)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAF\u0026thinsp;\u0026gt;\u0026thinsp;EU\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e181(0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e264\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e49(1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e74\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e35(0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e45`\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eEU\u0026thinsp;\u0026gt;\u0026thinsp;AF\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e83(2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e25(1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e10(0)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"7\" nameend=\"c7\" namest=\"c1\"\u003e \u003cp\u003e\u0026cap;: Denotes shared DEGs between the iOPC and iOL clusters\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec15\" class=\"Section2\"\u003e \u003ch2\u003eAncestry-dependent changes in AD\u003c/h2\u003e \u003cp\u003eWe compared the DEGs obtained from the different comparisons to genes currently implicated as AD GWAS loci [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e, \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e, \u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e, \u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e]. We found eleven AD GWAS genes (\u003cem\u003eALCAM, APP, COX7C, EGFR, GPC6, MYO15A, PLCG2, RTN1, SEC61G, SORL1, and TMEM106B\u003c/em\u003e) to be differentially expressed between the ancestries in the iOPC cluster (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eA, Table\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e). On the other hand, in the iOL cluster, only five AD GWAS hits were differentially expressed: \u003cem\u003eADAM17, CLU, EPDR1, FGF12, MAF and WWOX\u003c/em\u003e (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eB, Table\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e). One additional interesting DEG was \u003cem\u003eOPCML\u003c/em\u003e, a gene that has recently been linked to AD [\u003cspan additionalcitationids=\"CR39\" citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e]; in this case, we found it to be increased in Europeans compared with Africans.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab3\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eDifferentially expressed AD GWAS genes across ancestries\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"5\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eComparison\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eGene\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eFold Change\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003ep_val_adj\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eDEG between males and females*\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"8\" rowspan=\"9\"\u003e \u003cp\u003eAF vs AI OPC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cem\u003eGPC6\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.27\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e8.24E-09\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cem\u003eALCAM\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.26\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.42E-10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cem\u003eAPP\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.26\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.83E-04\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cem\u003eCOX7C\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-1.30\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.66E-02\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cem\u003eSEC61G\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-1.38\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.49E-02\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cem\u003eRTN1\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-1.48\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e6.21E-04\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cem\u003eEGFR\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-1.82\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.83E-06\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cem\u003eSORL1\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-1.96\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2.57E-17\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cem\u003eMYO15A\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-3.26\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e7.87E-03\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"8\" rowspan=\"9\"\u003e \u003cp\u003eEU vs AI OPC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cem\u003eFGF12\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.52\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2.77E-06\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cem\u003eCTSB\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-1.39\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4.80E-03\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cem\u003eCOX7C\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-1.43\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e8.05E-17\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cem\u003ePLCG2\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-1.46\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e5.08E-11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cem\u003eTMEM106B\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-1.47\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.63E-08\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cem\u003eENC1\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-1.48\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.45E-02\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cem\u003eSORL1\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-1.64\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.94E-08\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eYes\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cem\u003eSEC61G\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-1.76\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e5.28E-15\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cem\u003eEGFR\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-1.88\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3.57E-18\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eEU vs AF OPC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cem\u003eGPC6\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-1.31\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e9.75E-05\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eNot applicable\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cem\u003ePLCG2\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-1.61\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e7.95E-10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eNot applicable\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eAF vs AI OL\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cem\u003eWWOX\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-1.34\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.95E-05\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cem\u003eMAF\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-2.20\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.47E-02\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"2\" rowspan=\"3\"\u003e \u003cp\u003eEU vs AI OL\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cem\u003eWWOX\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-1.33\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e9.59E-03\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cem\u003eADAM17\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-1.56\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2.40E-03\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cem\u003eEPDR1\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-2.01\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4.98E-02\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eNo\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eEU vs AF OL\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cem\u003eFGF12\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1.27\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3.16E-02\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eNot applicable\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cem\u003eCLU\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-1.63\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3.75E-02\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eNot applicable\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"5\" nameend=\"c5\" namest=\"c1\"\u003e \u003cp\u003e*Found to be differentially expressed between AI male and AI female samples in this study (Tables S4 and S8)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec16\" class=\"Section2\"\u003e \u003ch2\u003eTranscriptome comparisons between APOE 3/3 vs APOE 4/4\u003c/h2\u003e \u003cp\u003eTo investigate the transcriptional changes that occur in oligodendroglia dependent on the \u003cem\u003eAPOE\u003c/em\u003e genotype, we compared the \u003cem\u003eAPOE3/3\u003c/em\u003e lines with the \u003cem\u003eAPOE4/4\u003c/em\u003e lines irrespective of their ancestry. For the larger iOPC cluster, there were 5,578 DEGs (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eA, Table S17), 30 of which are known AD GWAS loci; interestingly, most of them were upregulated in the 4/4 lines compared with the 3/3 lines (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eA,\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eB), with the exceptions of \u003cem\u003eIGF1R, IDUA, SORT1, ALCAM, MGMT, FGF12\u003c/em\u003e and \u003cem\u003eARAP1.\u003c/em\u003e In the iOL cluster, we identified 1,653 DEGs, including 9 AD GWAS genes namely, \u003cem\u003eRTN1, VSNL1, SORL1, COX7C, ANK3, ALCAM, ADAM10, IGF1R\u003c/em\u003e and \u003cem\u003eMGMT\u003c/em\u003e (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eC, \u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eD, Table S18). A total of 1,075 DEGs were shared by both clusters, including the AD GWAS genes \u003cem\u003eALCAM, ANK3, COX7C, IGF1R, MGMT, RTN1, SORL1\u003c/em\u003e and \u003cem\u003eVSNL1\u003c/em\u003e (Tables S17 and 18).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eTo determine whether the overlapping DEGs in oligodendroglia when analyzed by \u003cem\u003eAPOE\u003c/em\u003e genotype and AD status were involved in specific processes, we performed pathway analysis on these DEGs (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003e). These analyses showed that a wide range of pathways, especially those associated with neurodegenerative diseases, are significantly upregulated in APOE4/4 carrier iOPCs compared to \u003cem\u003eAPOE3/3\u003c/em\u003e carriers. Many of these pathways are involved in neurodegenerative diseases, including Alzheimer\u0026rsquo;s disease, Parkinson\u0026rsquo;s disease, and Huntington\u0026rsquo;s disease (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eA). Interestingly, fewer disease-related and more general pathways were identified in iOLs (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eB). The largest number of genes in iOPCs were involved in metabolic pathways, which led us to test for those involved in cholesterol biosynthesis. Indeed, a large number of DEGS were specifically increased in the cholesterol biosynthesis pathway in \u003cem\u003eAPOE4/4s\u003c/em\u003e compared to \u003cem\u003eAPOE3/3\u003c/em\u003e iOPCs (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003e). Further, we observed reduced expression of \u003cem\u003eMBP, PDGFRA\u003c/em\u003e, and \u003cem\u003eMYRF\u003c/em\u003e, key genes in myelin formation in the \u003cem\u003eAPOE4/4\u003c/em\u003e iOPC lines. Finally, Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eC and \u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eD shows pathway differences observed between NCI and AD iOPCs and iOLs. These pathways were similar to those seen in the APOE 3/3 vs APOE 4/4 comparison likely due to the fact that the majority of AD samples had the \u003cem\u003eAPOE4/4\u003c/em\u003e genotype.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec17\" class=\"Section2\"\u003e \u003ch2\u003eiOPC and iOLs correlated well with brain transcriptomes\u003c/h2\u003e \u003cp\u003eTo further validate the identity of our oligodendroglia, we ran Spearman correlation tests to compare our iOPC and OLs iOLs with gene expression patterns from the same cell types in human brain samples [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]. The correlation coefficient between iOPCs and brain OPCs was 0.89 and that between iOLs and brain OLs was 0.85, suggesting that our iOligodendroglia are transcriptionally similar to brain oligodendroglia from aged individuals.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec18\" class=\"Section2\"\u003e \u003ch2\u003eMales vs Females Expression\u003c/h2\u003e \u003cp\u003eTo account for sex-driven differences, given that most of our samples were females, except for two of the Amerindian lines, we performed differential expression analyses between the two AI males and the two AI females. It is worth noting that we observed loss of X chromosome inactivation (chromosome X erosion) in the female AI samples (Tables S4 and S8) [\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e], suggesting that the expression of genes on the X chromosomes and those influenced by them could be affected. Y chromosome genes were expressed as expected (e.g. \u003cem\u003eUTY\u003c/em\u003e and \u003cem\u003eUSP9Y\u003c/em\u003e were expressed in the male derived spheroids but not the female derived). We found that \u003cem\u003eALCAM\u003c/em\u003e, \u003cem\u003eGPC6\u003c/em\u003e and \u003cem\u003eSORL1\u003c/em\u003e were differentially expressed between males and females in the iOPC cluster (Tables\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e and S4). On the other hand, none of the AD GWAS genes that were differentially expressed between ancestries were differentially expressed between males and females in the iOL cluster (Tables\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e and S8).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec19\" class=\"Section2\"\u003e \u003ch2\u003ePathway analysis between ancestries\u003c/h2\u003e \u003cp\u003ePathway analysis between ancestries is shown in Fig.\u0026nbsp;\u003cspan refid=\"Fig7\" class=\"InternalRef\"\u003e7\u003c/span\u003e. Oxygen species production, diabetic cardiomyopathy, steroid biosynthesis, and several neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Alzheimer's disease, were identified in the pathway analyses. Interestingly, pathways of neurodegeneration implicated in multiple diseases, including Alzheimer's disease, were shown to be enriched for DEGs in Amerindian iOPC and iOL compared with those from European and African ancestries (Fig.\u0026nbsp;\u003cspan refid=\"Fig7\" class=\"InternalRef\"\u003e7\u003c/span\u003eC and Fig.\u0026nbsp;\u003cspan refid=\"Fig7\" class=\"InternalRef\"\u003e7\u003c/span\u003eD). The DEGs whose expression was increased in European oligodendroglia compared with Amerindian oligodendroglia did not appear to converge into any defined pathways. Finally, in the European vs. African comparison, the DEGs enriched in the European samples were also involved in several neurodegenerative disease pathways, specifically Huntington's disease and ALS, in addition to neuronal signaling processes (Fig.\u0026nbsp;\u003cspan refid=\"Fig7\" class=\"InternalRef\"\u003e7\u003c/span\u003eE).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003eSingle-nucleus chromatin accessibility profiling of iPSC-derived oligodendroglia-enriched neural spheroids across diverse ancestries.\u003c/b\u003e \u003c/p\u003e \u003cp\u003eTo characterize chromatin accessibility profiles associated with different ancestries, we performed single-nuclei ATAC sequencing of oligodendroglia enriched in neural spheroids derived from the 12 iPSC lines. We characterized a total of 76,409 nuclei, with an average of 6,367\u0026thinsp;\u0026plusmn;\u0026thinsp;3,994 per line. ArchR-based pattern recognition clustering identified 8 cell type clusters shared by all the individual samples (Fig.\u0026nbsp;\u003cspan refid=\"Fig8\" class=\"InternalRef\"\u003e8\u003c/span\u003eA). Based on marker genes, we identified one OPC (C6) cluster and one oligodendrocyte cluster (C7) (Fig.\u0026nbsp;\u003cspan refid=\"Fig8\" class=\"InternalRef\"\u003e8\u003c/span\u003eB).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eTo investigate the ancestry-related changes in chromatin accessibility in the oligodendroglia clusters, we performed pairwise comparisons of the iOPC and iOL clusters independently (shown in Fig.\u0026nbsp;\u003cspan refid=\"Fig9\" class=\"InternalRef\"\u003e9\u003c/span\u003e). For the AF vs. AI comparison in the iOPC cluster, we found 412 differentially peaks (DAPs) distributed across 357 genes, including \u003cem\u003eRBFOX1, PRDM7\u003c/em\u003e, \u003cem\u003eNCK2, EPDR1, and IQCK\u003c/em\u003e (AD GWAS hits) (Fig.\u0026nbsp;\u003cspan refid=\"Fig9\" class=\"InternalRef\"\u003e9\u003c/span\u003eA, Table S9). The number of DAPs between EU and AI was 413, belonging to 351 different genes, including the AD GWAS genes \u003cem\u003eADAM17, BIN1, CTSB, ECHDC3, EGFR, IGF1R, MAPT, MGMT\u003c/em\u003e, and \u003cem\u003eRBFOX1\u003c/em\u003e (Fig.\u0026nbsp;\u003cspan refid=\"Fig9\" class=\"InternalRef\"\u003e9\u003c/span\u003eB, Table S10). We also found DAPs associated with \u003cem\u003eFGF12\u003c/em\u003e and \u003cem\u003ePRDM7\u003c/em\u003e, but these same peaks were also found when we compared the two female AI lines to the two male AI lines, limiting our ability to distinguish ancestry-related or sex-related differences in these genes. When comparing the EU to the AF, we found a total of 457 DAPs (Fig.\u0026nbsp;\u003cspan refid=\"Fig9\" class=\"InternalRef\"\u003e9\u003c/span\u003eC, Table S11). These peaks were distributed across 373 genes, including four AD GWAS hits: \u003cem\u003eRBFOX1, PRDM7, FGF12, JAZF1, PRDM7, PRDM7\u003c/em\u003e, and \u003cem\u003eIQCK.\u003c/em\u003e On the other hand, for the iOL cluster, the greatest number of DAPs was found between AI and EU, with a total of 162 DAPs across 139 genes, including \u003cem\u003ePDRM7\u003c/em\u003e, \u003cem\u003eADAMTS1\u003c/em\u003e, and \u003cem\u003eREXO1\u003c/em\u003e (Fig.\u0026nbsp;\u003cspan refid=\"Fig9\" class=\"InternalRef\"\u003e9\u003c/span\u003eE). However, these DAPs were also found in the male vs. female comparison suggesting that the differences seen in accessibility of these genes could be due to sex differences rather than ancestry. We identified 73 DAPs across 63 genes, including a peak in \u003cem\u003ePDRM7\u003c/em\u003e that was also present in the male vs. female analysis in the comparison between AFs and AIs (Fig.\u0026nbsp;\u003cspan refid=\"Fig10\" class=\"InternalRef\"\u003e10\u003c/span\u003eE). Finally, we found 49 DAPs across 39 genes between Africans and Europeans, including the AD GWAS risk gene \u003cem\u003eFGF12\u003c/em\u003e (Fig.\u0026nbsp;\u003cspan refid=\"Fig10\" class=\"InternalRef\"\u003e10\u003c/span\u003eF).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec20\" class=\"Section2\"\u003e \u003ch2\u003eGenomic Regulatory Architecture\u003c/h2\u003e \u003cp\u003eTo examine the relationship between DEG and DAPs, we compared the genes associated with the DAPs with those that showed differential expression for each pairwise comparison in both oligodendroglia clusters \u0026ndash; iOPCs and iOLs (Fig.\u0026nbsp;\u003cspan refid=\"Fig10\" class=\"InternalRef\"\u003e10\u003c/span\u003e). In the iOPC cluster, we identified 60 genes that were differentially accessible and differentially expressed between Amerindians and Africans (Fig.\u0026nbsp;\u003cspan refid=\"Fig10\" class=\"InternalRef\"\u003e10\u003c/span\u003eA, Table S9). To account for sex-driven differences, we performed differential accessibility analyses comparing the 2 AI males to the 2 AI females (Table S12). Only 17 of the 60 were not found to be differentially expressed/accessible in the comparisons between males and females (Tables S4, S8, S12 and S16); for all of them, increased accessibility was correlated with increased expression. For the AI vs. EU comparison, we found 49 genes that were differentially accessible and differentially expressed; of these, 3 were previously reported AD GWAS genes (\u003cem\u003eCTSB, EGFR\u003c/em\u003e and \u003cem\u003eFGF12\u003c/em\u003e) [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e] (Fig.\u0026nbsp;\u003cspan refid=\"Fig10\" class=\"InternalRef\"\u003e10\u003c/span\u003eB, Table S10). Among these 49 genes, 23 were not affected by sex and 87% of this accessibility was correlated with expression. The exceptions were \u003cem\u003eMAP2, PPP2R2A\u003c/em\u003e and \u003cem\u003ePDXDC1\u003c/em\u003e; however, the last gene had two peaks, one in the promoter that correlated with expression and one in an exon that showed an inverse correlation (Table \u003cspan refid=\"MOESM2\" class=\"InternalRef\"\u003eS2\u003c/span\u003e and S10). Finally, in the AF vs. EU comparison, we found 22 DAGs that overlapped with the DEGs we identified (Fig.\u0026nbsp;\u003cspan refid=\"Fig10\" class=\"InternalRef\"\u003e10\u003c/span\u003eC); in all cases, accessibility correlated with expression, but for one of the genes harboring 2 DAPs, only one located in the promoter region correlated, whereas the other, located at an intron, showed the opposite trend (Table \u003cspan refid=\"MOESM3\" class=\"InternalRef\"\u003eS3\u003c/span\u003e and S11). In the iOL cluster, we found 10 overlapping DAGs and DEGs in the AI versus AF comparison (Fig.\u0026nbsp;\u003cspan refid=\"Fig10\" class=\"InternalRef\"\u003e10\u003c/span\u003eD, Table \u003cspan refid=\"MOESM5\" class=\"InternalRef\"\u003eS5\u003c/span\u003e and S13), 3 of which were not affected by sex and had direct correlation between accessibility and expression, and 10 in the AI versus EU comparison (Fig.\u0026nbsp;\u003cspan refid=\"Fig10\" class=\"InternalRef\"\u003e10\u003c/span\u003eE, Table \u003cspan refid=\"MOESM6\" class=\"InternalRef\"\u003eS6\u003c/span\u003e and S14); of these, 7 were not found to be influenced by sex (Table S16), and the accessibility of the peaks was in accordance with their expression.\u003c/p\u003e \u003cp\u003e \u003cb\u003eAncestry-specific differences in\u003c/b\u003e \u003cb\u003eFGF12\u003c/b\u003e \u003cb\u003echromatin openness and expression\u003c/b\u003e\u003c/p\u003e \u003cp\u003eWhen we looked at the DAP linked to \u003cem\u003eFGF12\u003c/em\u003e (Fig.\u0026nbsp;\u003cspan refid=\"Fig11\" class=\"InternalRef\"\u003e11\u003c/span\u003e, yellow highlight, Table S15), we observed that accessibility was correlated with \u003cem\u003eFGF12\u003c/em\u003e expression (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eB), as shown by the absence of a open chromatin peak in the EU lines and corresponding reduction in FGF12 expression in EU compared with the other two ancestries. Interestingly, within this peak, there is a site registered on ENCODE as a candidate cis-regulatory element with a proximal enhancer-like signature \u0026ndash; histone modification H3K4me3 (ENCODE Accession: EH38E2269814) (Fig.\u0026nbsp;\u003cspan refid=\"Fig11\" class=\"InternalRef\"\u003e11\u003c/span\u003e). Additionally, ORegAnno analysis showed this region also contains a transcription factor binding site for CTCF (ORegAnno ID: OREG1365260) (Fig.\u0026nbsp;\u003cspan refid=\"Fig11\" class=\"InternalRef\"\u003e11\u003c/span\u003e). Further, Hi-C analyses showed chromatin loops occurring between this ATAC peak and the transcriptional start site of the non-coding RNA ENSG00000289165, an antisense to \u003cem\u003eFGF12\u003c/em\u003e, in spheroids and brain samples (Fig.\u0026nbsp;\u003cspan refid=\"Fig11\" class=\"InternalRef\"\u003e11\u003c/span\u003e). This finding suggests that transcription of \u003cem\u003eFGF12\u003c/em\u003e could be modulated in an ancestry-dependent manner by this non-coding RNA.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003eAPOE\u003c/b\u003e \u003cb\u003egenotype-based comparisons\u003c/b\u003e\u003c/p\u003e \u003cp\u003eWhen comparing \u003cem\u003eAPOE3/3\u003c/em\u003e iOPCs to their \u003cem\u003eAPOE4/4\u003c/em\u003e counterparts, we identified a total of 67 DEGs that had corresponding DAPs. Of these, 3 were AD GWAS genes \u0026ndash; \u003cem\u003eEGFR, EPDR1\u003c/em\u003e, and \u003cem\u003eFGF12\u003c/em\u003e (Fig.\u0026nbsp;\u003cspan refid=\"Fig12\" class=\"InternalRef\"\u003e12\u003c/span\u003eA-B, Tables S17 and S21). Additionally, we identified a DAP associated to \u003cem\u003eADAM17\u003c/em\u003e (Fig.\u0026nbsp;\u003cspan refid=\"Fig12\" class=\"InternalRef\"\u003e12\u003c/span\u003eA-B)., a gene previously reported as an AD GWAS gene thought to be involved in TREM2 processing and regulating \u003cem\u003eAPP\u003c/em\u003e expression and therefore A\u0026szlig; formation [\u003cspan citationid=\"CR43\" class=\"CitationRef\"\u003e43\u003c/span\u003e]. On the other hand, in the iOL cluster, only 16 DEGs with corresponding DAPs were identified. None of these iOligodendroglia-specific DAPs have, as of yet, been linked to AD (Fig.\u0026nbsp;\u003cspan refid=\"Fig12\" class=\"InternalRef\"\u003e12\u003c/span\u003eC-D, Tables S17 and S21).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec21\" class=\"Section2\"\u003e \u003ch2\u003eDisease status-based comparisons\u003c/h2\u003e \u003cp\u003eWhen comparing the NCI lines to AD iOligidendroglia, we identified 38 DEGs that had corresponding DAPs, including 2 AD GWAS genes \u0026ndash; \u003cem\u003eFGF12\u003c/em\u003e and \u003cem\u003eMGMT\u003c/em\u003e (Fig.\u0026nbsp;\u003cspan refid=\"Fig13\" class=\"InternalRef\"\u003e13\u003c/span\u003eA-B, Tables S19 and S23). Additionally, we identified DAPs associated with \u003cem\u003eEPDR1\u003c/em\u003e and \u003cem\u003eJAZF1\u003c/em\u003e, but these genes were not differentially expressed in this comparison (Fig.\u0026nbsp;\u003cspan refid=\"Fig13\" class=\"InternalRef\"\u003e13\u003c/span\u003eA-B). Finally, in the OL cluster, we found only 2 DEGs with DAPs, none of which were AD GWAS genes (Fig.\u0026nbsp;\u003cspan refid=\"Fig13\" class=\"InternalRef\"\u003e13\u003c/span\u003eC-D Tables S20 and S24).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e"},{"header":"Discussion","content":"\u003cp\u003eIn this study, we compared the chromatin accessibility and transcriptomes of the three different ancestries that contribute to the African American and Hispanic/Latino admixed populations. Most previous studies have focused on the analysis of Europeans. Thus, this study provides new information and iPSC resources on these previously underrepresented ancestries. While we are focused on AD, the data generated can be more broadly applied to other disorder involving OPCs and OLs.\u003c/p\u003e \u003cp\u003eOverall, our studies show that chromatin accessibility and transcriptomes are similar for the three ancestries, although several key known AD genes showed ancestry-specific patterns of expression and/or chromatin openness that may reflect differences in risk between the ancestries. This ancestral similarity was particularly true for the chromatin structure analyses (ATACseq). Our data supports that DEG and DAP for the corresponding genes at AD GWAS loci are not a major factor in most comparisons. This is not to say that the AD (or other disease) GWAS loci that have common or different patterns of expression and chromatin openness will have similar causal mechanisms. We may well find that chromatin conformation analysis (i.e. Hi-C studies) will identify unique differences. Further, while single nuclei approaches have significant power to identify differences between individuals, the overall representation of a population is limited by the number of individuals that can be included in iPSC studies. However, the similarity between ancestries in both accessibility and expression in iOPC and iOLs across the majority of genes is reassuring for future therapeutic efforts in AD.\u003c/p\u003e \u003cp\u003eBoth \u003cem\u003eAPOE4/4\u003c/em\u003e and \u003cem\u003eAPOE3/3\u003c/em\u003e carriers across all the ancestries were included in this study. We found that \u003cem\u003eAPOE4/4\u003c/em\u003e carriers across all ancestries and in multiple individuals had clear upregulated expression of genes involved in cholesterol biosynthesis, particularly in iOPCs. The lower numbers of differential genes in iOLs could be due to the relatively fewer numbers of these cells found in this cluster within these cultures. This finding builds upon a similar observation seen in \u003cem\u003eAPOE4/4\u003c/em\u003e oligodendrocytes and OPCs from brain prefrontal cortex in previous studies [\u003cspan citationid=\"CR44\" class=\"CitationRef\"\u003e44\u003c/span\u003e]. Blanchard et al found similar results in a single isogenic \u003cem\u003eAPOE 3/3\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;\u0026gt;\u0026thinsp;\u003cem\u003eAPOE4/4\u003c/em\u003e iOL line [\u003cspan citationid=\"CR44\" class=\"CitationRef\"\u003e44\u003c/span\u003e]. Thus, cholesterol dysregulation appears to occur early in life during early stages in the development of oligodendrocytes (OPC) leading to impaired cholesterol and lipid biosynthesis. Even mild differences in cholesterol and lipid metabolism by oligodendroglia, occurring over the course of a lifetime, could produce pathogenic results. Indeed, research has highlighted the importance of white matter abnormalities in AD, including those involving oligodendroglia and myelin [\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e, \u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e, \u003cspan additionalcitationids=\"CR46\" citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e]. White matter abnormalities are considered early neuropathological events in AD since white matter hyperintensities, suggesting damage, have been observed preceding the development of AD symptoms [\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e]. These irregularities in white matter may play a significant role in the pathogenesis of AD and be of considerable diagnostic value [\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e]. Clinically, there have been reports of early AD-associated anatomical changes in infants and children. For example, Dean et al., reported that in areas affected by AD infants carrying \u003cem\u003eAPOE4\u003c/em\u003e had lower white matter myelin water fractions on magnetic resonance imaging (MRI) compared to non-carriers [\u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e48\u003c/span\u003e]. Further, Remer et al., found in young \u003cem\u003eAPOE4\u003c/em\u003e carriers a slower rate of myelination in multiple brain regions compared to that of non-carriers [\u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e49\u003c/span\u003e]. Thus, our findings in iOPCs and OPCs have potential implications for future timing of therapy for \u003cem\u003eAPOE4\u003c/em\u003e carriers [\u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e50\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eWe showed that our 3D neural spheroids produce brain-like oligodendroglia with transcriptomes that had high correlation\u0026thinsp;\u0026gt;\u0026thinsp;85% with human brain oligodendroglia datasets, including OPCs and a population of early myelinating oligodendrocytes characterized by high expression of \u003cem\u003eBCAS1\u003c/em\u003e (Fard et al., 2017). Additionally, we observed that our ancestry-based data replicates findings from human brain studies. For example, we found \u003cem\u003eCLU\u003c/em\u003e to be differentially expressed between AF and EU iOLs as previously reported by Griswold et al. in AD human brains [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]. These observations suggest that iOPC and iOLs are a good model to study oligodendroglia that effectively reflects phenomena occurring \u003cem\u003ein vivo\u003c/em\u003e in human brains.\u003c/p\u003e \u003cp\u003eOPCs, which are central nervous system (CNS) resident stem cells that are spread throughout the brain forming a category of mobile and actively dividing adult precursor cells capable of developing into oligodendrocytes [\u003cspan citationid=\"CR51\" class=\"CitationRef\"\u003e51\u003c/span\u003e]. OPCs play a very important role in the response to myelin damage due to injury or disease, as they are responsible for maintaining the population of oligodendrocytes and participate in myelin repair [\u003cspan citationid=\"CR52\" class=\"CitationRef\"\u003e52\u003c/span\u003e, \u003cspan citationid=\"CR53\" class=\"CitationRef\"\u003e53\u003c/span\u003e]. In AD, the brain's microenvironment undergoes detrimental changes that significantly impact OPCs and their functionality [\u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e54\u003c/span\u003e]. The observed changes in OPCs suggest reduced differentiation capacity and elevated OPC senescence [\u003cspan citationid=\"CR55\" class=\"CitationRef\"\u003e55\u003c/span\u003e]. These changes can have implications for myelin maintenance and repair, as well as for the overall integrity of the central nervous system [\u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e54\u003c/span\u003e, \u003cspan citationid=\"CR55\" class=\"CitationRef\"\u003e55\u003c/span\u003e], thereby making OPCs a highly relevant cell population for the study of AD.\u003c/p\u003e \u003cp\u003eIn this context, this report is the first study focusing on human iPSC-derived oligodendroglia that includes samples from different ancestries. When we isolated the pathway changes in cholesterol biosynthesis to specific ancestries, we found that several of the cholesterol biosynthesis genes are increased in AI compared to AF and EU Oligodendroglia (Tables S4 and S8). This finding is interesting in light of epidemiological observations in AI populations which suggest that evolutionary pressures favored the increased expression of lipid metabolism genes (including \u003cem\u003eAPOE4\u003c/em\u003e) to overcome food scarcity and endemic infectious diseases (high cholesterol supports innate immunity) in AI groups, particularly in Indigenous groups in South America [\u003cspan citationid=\"CR56\" class=\"CitationRef\"\u003e56\u003c/span\u003e]. This is also believed to be a reason \u003cem\u003eAPOE4\u003c/em\u003e has its highest global frequency in specific regions of South America and Africa [\u003cspan citationid=\"CR57\" class=\"CitationRef\"\u003e57\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eFinally, the inclusion of multiple ancestries in AD research not only supports the importance of reducing health disparities in AD, the comparison of differences between ancestries is a useful research tool in exploring the mechanisms of disease. While the outcome of AD may be similar across ancestral populations, the starting points and biological paths taken in the development of AD may differ between genetic ancestries and environments. Thus, studies on diverse populations provide novel windows into the pathology of AD which will only help move us towards the ultimate goal of prevention.\u003c/p\u003e"},{"header":"CONCLUSIONS","content":"\u003cp\u003eThis study represents a significant advancement in understanding the ancestry-specific differences in iPSC-derived oligodendroglia and their implications for Alzheimer's disease (AD). By generating and analyzing iPSC lines from AF, AI, and EU ancestries, we have identified unique transcriptional and chromatin accessibility profiles in genes that may contribute to AD risk.\u003c/p\u003e \u003cp\u003eOur findings emphasize the importance of including diverse ancestries in iPSC studies to uncover subtle yet crucial differences that may impact disease susceptibility and progression. The differential expression and accessibility of genes associated with AD across ancestries, such as APOE, highlight potential pathways that could be targeted for therapeutic interventions. Notably, the upregulation of cholesterol biosynthesis genes in AI iPSC-derived oligodendroglia suggests evolutionary adaptations that may confer advantages in certain environments. Although these alterations may promote survival in the face of potential food scarcities, they may have come at the cost of increasing risk for AD development.\u003c/p\u003e \u003cp\u003eThis study also underscores the role of \u003cem\u003eAPOE\u003c/em\u003e genotype in modulating gene expression related to lipid metabolism, providing insights into early intervention strategies for \u003cem\u003eAPOE4\u003c/em\u003e carriers. The correlation between our iPSC-derived models and human brain oligodendroglia strengthens the validity of using these models to study neurodegenerative diseases, offering a promising avenue for future research in AD biology and therapeutic development.\u003c/p\u003e \u003cp\u003eFinally, this work not only sheds light on the molecular underpinnings of AD across different genetic backgrounds but also underscores the necessity to address health disparities by ensuring diverse representation in research. Understanding the distinct genetic and environmental pathways leading to AD in various populations will enhance our ability to develop effective, personalized prevention and treatment strategies.\u003c/p\u003e"},{"header":"Abbreviations","content":"\u003cdiv class=\"DefinitionList\"\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eAD\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eAlzheimer\u0026rsquo;s disease\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eMCI\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eMild cognitive impairment\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eNCI\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eNon cognitively impaired\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eGWAS\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eGenome wide association studies\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eGRA\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eGenomic regulatory architecture\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eAF\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eAfrican\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eAI\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eAmerindian\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eEU\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eEuropean\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eEA\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eEast Asian\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eWGS\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eWhole Genome Sequencing\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eiPSC\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003einduced pluripotent stem cells\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eOPC\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eOligodendrocyte precursor cells\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eOL\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eOligodendrocytes\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eiOPC\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eiPSC derived OPC\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eiOL\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eiPSC derived OL\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eDEG\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eDifferentially expressed gene\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eDAP\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eDifferentially accessible peak\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eDAG\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eDifferentially accessible gene\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eGA\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eGlobal ancestry\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003c/div\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe research protocols involving the collection of human samples were reviewed and approved by the Institutional Review Board (IRB) at the University of Miami. The IRB approval ID for this study is CR00001611. All procedures were conducted in accordance with ethical standards and guidelines for research involving human participants.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAvailability of data and materials\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll data generated and analyzed for this study are included in this published article and its supplementary information files. Additional raw files are available from the corresponding author upon reasonable request.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare that they have no competing interests.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis research was funded by the National Institute on Aging through the following grant numbers: U01-AG072579, RF1-AG059018, U01-AG066767, U01-AG052410, R56-AG072547, and R01-AG070864. Additional funding was received from a Zenith Award (Alzheimer’s Association, J.M.V) and the BrightFocus foundation.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors' contributions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eA.M.R., D.M.D., A.J.G., J.I.Y., and J.M.V. conceptualized the project and designed the experiments. A.M.R. conducted the experiments. A.M.R., L.B.N., and A.J.G. analyzed the data. S.M, and L.C. contributed to the execution of the experiments and performed the iPSC reprogramming, while B.A.D. assisted with this process. J.R. and F.R. carried out local and global ancestry analyses. P.W., L.D.A., T.D.S., P.M., M.I.-M., S.T., G.B., M.C.-O., B.F.-A., and M.A.P.-V. were involved in sample collection and processing. L.W. and M.R. processed the samples for Hi-C analyses, W. X., F.J performed the bioinformatic analysis for the Hi-C data. \u0026nbsp;A.M.R., L.B.N., S.M., F.R., A.J.G., D.M.D., J.I.Y., and J.M.V. discussed the data results. A.M.R., L.B.N., A.J.G., D.M.D., J.I.Y., and J.M.V. wrote the manuscript. All authors reviewed and approved the final manuscript.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgements\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWe would like to thank the Center for Genome Technology (CGT) at the John P. Hussman Institute for Human Genomics (HIHG) at the University of Miami, Miller School of Medicine, for their support in processing the samples for library preparation and sequencing. We are also grateful to the many participants, researchers, and staff who contributed significantly to this study.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n \u003cli\u003eBellenguez, C., et al., \u003cem\u003eNew insights into the genetic etiology of Alzheimer\u0026apos;s disease and related dementias.\u003c/em\u003e Nat Genet, 2022. \u003cstrong\u003e54\u003c/strong\u003e(4): p. 412-436.\u003c/li\u003e\n \u003cli\u003eKunkle, B.W., et al., \u003cem\u003eGenome-wide linkage analyses of non-Hispanic white families identify novel loci for familial late-onset Alzheimer\u0026apos;s disease.\u003c/em\u003e Alzheimers Dement, 2016. \u003cstrong\u003e12\u003c/strong\u003e(1): p. 2-10.\u003c/li\u003e\n \u003cli\u003eKunkle, B.W., et al., \u003cem\u003eNovel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel: A Meta-analysis.\u003c/em\u003e JAMA Neurol, 2021. \u003cstrong\u003e78\u003c/strong\u003e(1): p. 102-113.\u003c/li\u003e\n \u003cli\u003eLake, J., et al., \u003cem\u003eMulti-ancestry meta-analysis and fine-mapping in Alzheimer\u0026apos;s disease.\u003c/em\u003e Mol Psychiatry, 2023. \u003cstrong\u003e28\u003c/strong\u003e(7): p. 3121-3132.\u003c/li\u003e\n \u003cli\u003ede Rojas, I., et al., \u003cem\u003eCommon variants in Alzheimer\u0026apos;s disease and risk stratification by polygenic risk scores.\u003c/em\u003e Nat Commun, 2021. \u003cstrong\u003e12\u003c/strong\u003e(1): p. 3417.\u003c/li\u003e\n \u003cli\u003eNaj, A.C., G.D. Schellenberg, and C. Alzheimer\u0026apos;s Disease Genetics, \u003cem\u003eGenomic variants, genes, and pathways of Alzheimer\u0026apos;s disease: An overview.\u003c/em\u003e Am J Med Genet B Neuropsychiatr Genet, 2017. \u003cstrong\u003e174\u003c/strong\u003e(1): p. 5-26.\u003c/li\u003e\n \u003cli\u003eXue, D., et al., \u003cem\u003eLarge-scale sequencing studies expand the known genetic architecture of Alzheimer\u0026apos;s disease.\u003c/em\u003e Alzheimers Dement (Amst), 2021. \u003cstrong\u003e13\u003c/strong\u003e(1): p. e12255.\u003c/li\u003e\n \u003cli\u003eLill, C.M. and L. Bertram, \u003cem\u003eGenome-wide analysis furthers decoding of Alzheimer disease genetics.\u003c/em\u003e Nat Rev Neurol, 2022. \u003cstrong\u003e18\u003c/strong\u003e(7): p. 387-388.\u003c/li\u003e\n \u003cli\u003eLambert, J.C., et al., \u003cem\u003eMeta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer\u0026apos;s disease.\u003c/em\u003e Nat Genet, 2013. \u003cstrong\u003e45\u003c/strong\u003e(12): p. 1452-8.\u003c/li\u003e\n \u003cli\u003eBeecham, G.W., et al., \u003cem\u003eThe Alzheimer\u0026apos;s Disease Sequencing Project: Study design and sample selection.\u003c/em\u003e Neurol Genet, 2017. \u003cstrong\u003e3\u003c/strong\u003e(5): p. e194.\u003c/li\u003e\n \u003cli\u003eRajabli, F., et al., \u003cem\u003eA locus at 19q13.31 significantly reduces the ApoE epsilon4 risk for Alzheimer\u0026apos;s Disease in African Ancestry.\u003c/em\u003e PLoS Genet, 2022. \u003cstrong\u003e18\u003c/strong\u003e(7): p. e1009977.\u003c/li\u003e\n \u003cli\u003eMarca-Ysabel, M.V., et al., \u003cem\u003eDissecting the role of Amerindian genetic ancestry and the ApoE epsilon4 allele on Alzheimer disease in an admixed Peruvian population.\u003c/em\u003e Neurobiol Aging, 2021. \u003cstrong\u003e101\u003c/strong\u003e: p. 298 e11-298 e15.\u003c/li\u003e\n \u003cli\u003eFarrer, L.A., et al., \u003cem\u003eEffects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium.\u003c/em\u003e JAMA, 1997. \u003cstrong\u003e278\u003c/strong\u003e(16): p. 1349-56.\u003c/li\u003e\n \u003cli\u003eCelis, K., et al., \u003cem\u003eAncestry-related differences in chromatin accessibility and gene expression of APOE epsilon4 are associated with Alzheimer\u0026apos;s disease risk.\u003c/em\u003e Alzheimers Dement, 2023. \u003cstrong\u003e19\u003c/strong\u003e(9): p. 3902-3915.\u003c/li\u003e\n \u003cli\u003eGriswold, A.J., et al., \u003cem\u003eIncreased APOE epsilon4 expression is associated with the difference in Alzheimer\u0026apos;s disease risk from diverse ancestral backgrounds.\u003c/em\u003e Alzheimers Dement, 2021. \u003cstrong\u003e17\u003c/strong\u003e(7): p. 1179-1188.\u003c/li\u003e\n \u003cli\u003eRajabli, F., et al., \u003cem\u003eAncestral origin of ApoE epsilon4 Alzheimer disease risk in Puerto Rican and African American populations.\u003c/em\u003e PLoS Genet, 2018. \u003cstrong\u003e14\u003c/strong\u003e(12): p. e1007791.\u003c/li\u003e\n \u003cli\u003eBaumann, N. and D. Pham-Dinh, \u003cem\u003eBiology of oligodendrocyte and myelin in the mammalian central nervous system.\u003c/em\u003e Physiol Rev, 2001. \u003cstrong\u003e81\u003c/strong\u003e(2): p. 871-927.\u003c/li\u003e\n \u003cli\u003eCai, Z. and M. Xiao, \u003cem\u003eOligodendrocytes and Alzheimer\u0026apos;s disease.\u003c/em\u003e Int J Neurosci, 2016. \u003cstrong\u003e126\u003c/strong\u003e(2): p. 97-104.\u003c/li\u003e\n \u003cli\u003eNasrabady, S.E., et al., \u003cem\u003eWhite matter changes in Alzheimer\u0026apos;s disease: a focus on myelin and oligodendrocytes.\u003c/em\u003e Acta Neuropathol Commun, 2018. \u003cstrong\u003e6\u003c/strong\u003e(1): p. 22.\u003c/li\u003e\n \u003cli\u003eFeliciano-Astacio, B.E., et al., \u003cem\u003eThe Puerto Rico Alzheimer Disease Initiative (PRADI): A Multisource Ascertainment Approach.\u003c/em\u003e Front Genet, 2019. \u003cstrong\u003e10\u003c/strong\u003e: p. 538.\u003c/li\u003e\n \u003cli\u003eAkgun, B., et al., \u003cem\u003eGenome-wide association analysis and admixture mapping in a Puerto Rican cohort supports an Alzheimer disease risk locus on chromosome 12.\u003c/em\u003e Front Aging Neurosci, 2024. \u003cstrong\u003e16\u003c/strong\u003e: p. 1459796.\u003c/li\u003e\n \u003cli\u003eAlexander, D.H., J. Novembre, and K. Lange, \u003cem\u003eFast model-based estimation of ancestry in unrelated individuals.\u003c/em\u003e Genome Res, 2009. \u003cstrong\u003e19\u003c/strong\u003e(9): p. 1655-64.\u003c/li\u003e\n \u003cli\u003eClarke, L., et al., \u003cem\u003eThe international Genome sample resource (IGSR): A worldwide collection of genome variation incorporating the 1000 Genomes Project data.\u003c/em\u003e Nucleic Acids Res, 2017. \u003cstrong\u003e45\u003c/strong\u003e(D1): p. D854-D859.\u003c/li\u003e\n \u003cli\u003eFairley, S., et al., \u003cem\u003eThe International Genome Sample Resource (IGSR) collection of open human genomic variation resources.\u003c/em\u003e Nucleic Acids Res, 2020. \u003cstrong\u003e48\u003c/strong\u003e(D1): p. D941-D947.\u003c/li\u003e\n \u003cli\u003eDelaneau, O., et al., \u003cem\u003eIntegrating sequence and array data to create an improved 1000 Genomes Project haplotype reference panel.\u003c/em\u003e Nat Commun, 2014. \u003cstrong\u003e5\u003c/strong\u003e: p. 3934.\u003c/li\u003e\n \u003cli\u003eGenomes Project, C., et al., \u003cem\u003eA global reference for human genetic variation.\u003c/em\u003e Nature, 2015. \u003cstrong\u003e526\u003c/strong\u003e(7571): p. 68-74.\u003c/li\u003e\n \u003cli\u003eDouvaras, P. and V. Fossati, \u003cem\u003eGeneration and isolation of oligodendrocyte progenitor cells from human pluripotent stem cells.\u003c/em\u003e Nat Protoc, 2015. \u003cstrong\u003e10\u003c/strong\u003e(8): p. 1143-54.\u003c/li\u003e\n \u003cli\u003eFinak, G., et al., \u003cem\u003eMAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data.\u003c/em\u003e Genome Biol, 2015. \u003cstrong\u003e16\u003c/strong\u003e: p. 278.\u003c/li\u003e\n \u003cli\u003eSoneson, C. and M.D. Robinson, \u003cem\u003eBias, robustness and scalability in single-cell differential expression analysis.\u003c/em\u003e Nat Methods, 2018. \u003cstrong\u003e15\u003c/strong\u003e(4): p. 255-261.\u003c/li\u003e\n \u003cli\u003eKolberg, L., et al., \u003cem\u003egprofiler2 -- an R package for gene list functional enrichment analysis and namespace conversion toolset g:Profiler.\u003c/em\u003e F1000Res, 2020. \u003cstrong\u003e9\u003c/strong\u003e.\u003c/li\u003e\n \u003cli\u003eGranja, J.M., et al., \u003cem\u003eArchR is a scalable software package for integrative single-cell chromatin accessibility analysis.\u003c/em\u003e Nat Genet, 2021. \u003cstrong\u003e53\u003c/strong\u003e(3): p. 403-411.\u003c/li\u003e\n \u003cli\u003eKorsunsky, I., et al., \u003cem\u003eFast, sensitive and accurate integration of single-cell data with Harmony.\u003c/em\u003e Nat Methods, 2019. \u003cstrong\u003e16\u003c/strong\u003e(12): p. 1289-1296.\u003c/li\u003e\n \u003cli\u003eZhang, Y., et al., \u003cem\u003eModel-based analysis of ChIP-Seq (MACS).\u003c/em\u003e Genome Biol, 2008. \u003cstrong\u003e9\u003c/strong\u003e(9): p. R137.\u003c/li\u003e\n \u003cli\u003eYu, G., L.G. Wang, and Q.Y. He, \u003cem\u003eChIPseeker: an R/Bioconductor package for ChIP peak annotation, comparison and visualization.\u003c/em\u003e Bioinformatics, 2015. \u003cstrong\u003e31\u003c/strong\u003e(14): p. 2382-3.\u003c/li\u003e\n \u003cli\u003eRao, S.S., et al., \u003cem\u003eA 3D map of the human genome at kilobase resolution reveals principles of chromatin looping.\u003c/em\u003e Cell, 2014. \u003cstrong\u003e159\u003c/strong\u003e(7): p. 1665-80.\u003c/li\u003e\n \u003cli\u003eKunkle, B.W., et al., \u003cem\u003eGenetic meta-analysis of diagnosed Alzheimer\u0026apos;s disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing.\u003c/em\u003e Nat Genet, 2019. \u003cstrong\u003e51\u003c/strong\u003e(3): p. 414-430.\u003c/li\u003e\n \u003cli\u003eZhang, L., et al., \u003cem\u003eEpigenome-wide meta-analysis of DNA methylation differences in prefrontal cortex implicates the immune processes in Alzheimer\u0026apos;s disease.\u003c/em\u003e Nat Commun, 2020. \u003cstrong\u003e11\u003c/strong\u003e(1): p. 6114.\u003c/li\u003e\n \u003cli\u003eLehrer, S. and P.H. Rheinstein, \u003cem\u003eRORB, an Alzheimer\u0026apos;s disease susceptibility gene, is associated with viral encephalitis, an Alzheimer\u0026apos;s disease risk factor.\u003c/em\u003e Clin Neurol Neurosurg, 2023. \u003cstrong\u003e233\u003c/strong\u003e: p. 107984.\u003c/li\u003e\n \u003cli\u003eWeller, A.E., et al., \u003cem\u003eSingle Nucleus Transcriptome Data from Alzheimer\u0026apos;s Disease Mouse Models Yield New Insight into Pathophysiology.\u003c/em\u003e J Alzheimers Dis, 2022. \u003cstrong\u003e90\u003c/strong\u003e(3): p. 1233-1247.\u003c/li\u003e\n \u003cli\u003eLiu, F., et al., \u003cem\u003eA genomewide screen for late-onset Alzheimer disease in a genetically isolated Dutch population.\u003c/em\u003e Am J Hum Genet, 2007. \u003cstrong\u003e81\u003c/strong\u003e(1): p. 17-31.\u003c/li\u003e\n \u003cli\u003eBrenes, A.J., et al., \u003cem\u003eErosion of human X chromosome inactivation causes major remodeling of the iPSC proteome.\u003c/em\u003e Cell Rep, 2021. \u003cstrong\u003e35\u003c/strong\u003e(4): p. 109032.\u003c/li\u003e\n \u003cli\u003eLiao, W., et al., \u003cem\u003eIdentification of candidate genes associated with clinical onset of Alzheimer\u0026apos;s disease.\u003c/em\u003e Front Neurosci, 2022. \u003cstrong\u003e16\u003c/strong\u003e: p. 1060111.\u003c/li\u003e\n \u003cli\u003eHartl, D., et al., \u003cem\u003eA rare loss-of-function variant of ADAM17 is associated with late-onset familial Alzheimer disease.\u003c/em\u003e Mol Psychiatry, 2020. \u003cstrong\u003e25\u003c/strong\u003e(3): p. 629-639.\u003c/li\u003e\n \u003cli\u003eBlanchard, J.W., et al., \u003cem\u003eAPOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes.\u003c/em\u003e Nature, 2022. \u003cstrong\u003e611\u003c/strong\u003e(7937): p. 769-779.\u003c/li\u003e\n \u003cli\u003eRadanovic, M., et al., \u003cem\u003eWhite matter abnormalities associated with Alzheimer\u0026apos;s disease and mild cognitive impairment: a critical review of MRI studies.\u003c/em\u003e Expert Rev Neurother, 2013. \u003cstrong\u003e13\u003c/strong\u003e(5): p. 483-93.\u003c/li\u003e\n \u003cli\u003eButt, A.M., I.C. De La Rocha, and A. Rivera, \u003cem\u003eOligodendroglial Cells in Alzheimer\u0026apos;s Disease.\u003c/em\u003e Adv Exp Med Biol, 2019. \u003cstrong\u003e1175\u003c/strong\u003e: p. 325-333.\u003c/li\u003e\n \u003cli\u003eKao, Y.H., et al., \u003cem\u003eWhite Matter Changes in Patients with Alzheimer\u0026apos;s Disease and Associated Factors.\u003c/em\u003e J Clin Med, 2019. \u003cstrong\u003e8\u003c/strong\u003e(2).\u003c/li\u003e\n \u003cli\u003eDean, D.C., 3rd, et al., \u003cem\u003eBrain differences in infants at differential genetic risk for late-onset Alzheimer disease: a cross-sectional imaging study.\u003c/em\u003e JAMA Neurol, 2014. \u003cstrong\u003e71\u003c/strong\u003e(1): p. 11-22.\u003c/li\u003e\n \u003cli\u003eRemer, J., et al., \u003cem\u003eLongitudinal white matter and cognitive development in pediatric carriers of the apolipoprotein epsilon4 allele.\u003c/em\u003e Neuroimage, 2020. \u003cstrong\u003e222\u003c/strong\u003e: p. 117243.\u003c/li\u003e\n \u003cli\u003eVance, J.M., et al., \u003cem\u003eReport of the APOE4 National Institute on Aging/Alzheimer Disease Sequencing Project Consortium Working Group: Reducing APOE4 in Carriers is a Therapeutic Goal for Alzheimer\u0026apos;s Disease.\u003c/em\u003e Ann Neurol, 2024.\u003c/li\u003e\n \u003cli\u003eKuhn, S., et al., \u003cem\u003eOligodendrocytes in Development, Myelin Generation and Beyond.\u003c/em\u003e Cells, 2019. \u003cstrong\u003e8\u003c/strong\u003e(11).\u003c/li\u003e\n \u003cli\u003eBeiter, R.M., et al., \u003cem\u003eEvidence for oligodendrocyte progenitor cell heterogeneity in the adult mouse brain.\u003c/em\u003e Sci Rep, 2022. \u003cstrong\u003e12\u003c/strong\u003e(1): p. 12921.\u003c/li\u003e\n \u003cli\u003eYun, W., et al., \u003cem\u003eOCT4-induced oligodendrocyte progenitor cells promote remyelination and ameliorate disease.\u003c/em\u003e NPJ Regen Med, 2022. \u003cstrong\u003e7\u003c/strong\u003e(1): p. 4.\u003c/li\u003e\n \u003cli\u003eZou, P., et al., \u003cem\u003eOligodendrocyte progenitor cells in Alzheimer\u0026apos;s disease: from physiology to pathology.\u003c/em\u003e Transl Neurodegener, 2023. \u003cstrong\u003e12\u003c/strong\u003e(1): p. 52.\u003c/li\u003e\n \u003cli\u003eVanzulli, I., et al., \u003cem\u003eDisruption of oligodendrocyte progenitor cells is an early sign of pathology in the triple transgenic mouse model of Alzheimer\u0026apos;s disease.\u003c/em\u003e Neurobiol Aging, 2020. \u003cstrong\u003e94\u003c/strong\u003e: p. 130-139.\u003c/li\u003e\n \u003cli\u003eSuchy-Dicey, A., et al., \u003cem\u003eAPOE genotype, hippocampus, and cognitive markers of Alzheimer\u0026apos;s disease in American Indians: Data from the Strong Heart Study.\u003c/em\u003e Alzheimers Dement, 2022. \u003cstrong\u003e18\u003c/strong\u003e(12): p. 2518-2526.\u003c/li\u003e\n \u003cli\u003eBelloy, M.E., et al., \u003cem\u003eAPOE Genotype and Alzheimer Disease Risk Across Age, Sex, and Population Ancestry.\u003c/em\u003e JAMA Neurol, 2023. \u003cstrong\u003e80\u003c/strong\u003e(12): p. 1284-1294.\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"","lastPublishedDoi":"10.21203/rs.3.rs-5338140/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-5338140/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eBackground:\u003c/h2\u003e \u003cp\u003eThis study aims to elucidate ancestry-specific changes to the genomic regulatory architecture in induced pluripotent stem cell (iPSC)-derived oligodendroglia, focusing on their implications for Alzheimer's disease (AD). This work addresses the lack of diversity in previous iPSC studies by including ancestries that contribute to African American (European/African) and Hispanic/Latino populations (Amerindian/African/European).\u003c/p\u003e\u003ch2\u003eMethods:\u003c/h2\u003e \u003cp\u003eWe generated 12 iPSC lines\u0026mdash;four African, four Amerindian, and four European\u0026mdash; from both AD patients and non-cognitively impaired individuals, with varying \u003cem\u003eAPOE\u003c/em\u003e genotypes (\u003cem\u003eAPOE3/3\u003c/em\u003e and \u003cem\u003eAPOE4/4\u003c/em\u003e). These lines were differentiated into neural spheroids containing oligodendrocyte lineage cells. Single-nuclei RNA sequencing and ATAC sequencing were employed to analyze transcriptional and chromatin accessibility profiles, respectively. Differential gene expression, chromatin accessibility, and Hi-C analyses were conducted, followed by pathway analysis to interpret the results.\u003c/p\u003e\u003ch2\u003eResults:\u003c/h2\u003e \u003cp\u003eWe identified ancestry-specific differences in gene expression and chromatin accessibility. Notably, numerous AD GWAS-associated genes were differentially expressed across ancestries. The largest number of differentially expressed genes (DEGs) were found in European vs. Amerindian and African vs. Amerindian iPSC-derived oligodendrocyte progenitor cells (OPCs). Pathway analysis of \u003cem\u003eAPOE4/4\u003c/em\u003e carriers vs \u003cem\u003eAPOE3/3\u003c/em\u003e carriers exhibited upregulation of a large number of disease and metabolic pathways in \u003cem\u003eAPOE4/4\u003c/em\u003e individuals of all ancestries. Of particular interest was that \u003cem\u003eAPOE4/4\u003c/em\u003e carriers had significantly upregulated cholesterol biosynthesis genes relative to \u003cem\u003eAPOE3/3\u003c/em\u003e individuals across all ancestries, strongest in iOPCs. Comparison of iOPC and iOL transcriptome data with corresponding human frontal cortex data demonstrated a high correlation (R\u003csup\u003e2\u003c/sup\u003e\u0026thinsp;\u0026gt;\u0026thinsp;0.85).\u003c/p\u003e\u003ch2\u003eConclusions:\u003c/h2\u003e \u003cp\u003eThis research emphasizes the importance of including diverse ancestries in AD research to uncover critical gene expression differences between populations and ancestries that may influence disease susceptibility and therapeutic interventions. The upregulation of cholesterol biosynthesis genes in \u003cem\u003eAPOE4/4\u003c/em\u003e carriers of all three ancestries supports the concept that \u003cem\u003eAPOE4\u003c/em\u003e may produce disease effects early in life, which could have therapeutic implications as we move forward towards specific therapy for \u003cem\u003eAPOE4\u003c/em\u003e carriers. These findings and the high correlation between brain and iPSC-derived OPC and OL transcriptomes support the relevance of this approach as a model for disease study.\u003c/p\u003e","manuscriptTitle":"Ancestral Genomic Functional Differences in Oligodendroglia: Implications for Alzheimer's Disease","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-12-04 16:20:12","doi":"10.21203/rs.3.rs-5338140/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"4ddb903b-d6d4-4e72-96bd-57bf9d6df569","owner":[],"postedDate":"December 4th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2025-03-06T20:27:02+00:00","versionOfRecord":[],"versionCreatedAt":"2024-12-04 16:20:12","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-5338140","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-5338140","identity":"rs-5338140","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}